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An inflammatory process in the central nervous system (CNS) is believed to 
play an important role in the pathway leading to neuronal cell death in a number of 
neurodegenerative diseases. The inflammatory response is mediated by the activated 
microglia, the resident immune cells of the CNS. In response to a variety of stimuli, 
microglia undergo rapid proliferation, secrete a number of proinflammatory 
cytokines, migrate to the injury sites, and remove the damaged cells by phagocytosis. 
Although microglia play a beneficial role in large by removing potentially toxic 
cellular debris, it remains controversial whether microglial cells have beneficial or 
detrimental functions in various neuropathological conditions. The chronic activation 
Summary 
 xvii
of microglia may cause neuronal damage through the release of potentially cytotoxic 
molecules such as proinflammatory cytokines including tumor necrosis factor-α 
(TNF-α) and reactive oxygen intermediates. Therefore, suppression of 
microglia-mediated inflammation has been considered as an important strategy in 
neurodegenerative disease therapy. Several anti-inflammatory drugs have been shown 
to repress the microglial activation and to exert neuroprotective effects in the CNS 
after different types of injuries. However, these drugs do not specifically target  
microglial cells and therefore, exhibit potential systemic side effects. In this study, we  
attempted to understand the potential mechanisms and signaling pathways by which 
two drugs, glucocorticoids (GCs) and all-trans-retinoid acid (RA), suppress the 
activation of microglial cells in CNS diseases.  
Dexamethasone inhibits chemotaxic activity of microglia: Microglial cells release 
monocyte chemotactic protein-1 (MCP-1) which is believed to amplify the 
inflammation process by recruiting macrophages and microglia to the inflammatory 
sites in CNS diseases. GCs are widely used anti-inflammatory and 
immunosuppressive drugs in several neurological diseases. Recently,  it has been 
shown that GCs could inhibit LPS-induced MCP-1 production in the hippocampus 
and cortex (Szczepanik and Ringheim 2003; Little et al. 2006). However, the 
molecular mechanisms by which GCs regulate MCP-1 expression in activated 
microglial cells have not been elucidated. It has been reported that GCs 
counter-regulate mitogen-activated protein kinase (MAPK) signaling pathways, in 
particular p38 and Jun N-terminal kinase (JNK) pathways by inducing expression 
Summary 
 xviii
MAPK phosphatase-1 (MKP-1) (Clark 2003). Moreover, activation of MAP Kinases 
in microglial cells, leads to phosphorylation of transcription factors such as 
c-Jun/AP-1 resulting in induction of expression of some target genes including TNF-α, 
and MCP-1 (Babcock et al., 2003; Waetzig et al., 2005). In view of these observations, 
it was hypothesized that GCs inhibit MCP-1 production via MKP-1-mediated 
inactivation of MAP Kinases, resulting in decreased microglial migration towards the 
sites of inflammation in the CNS. Hence, effects of dexamethasone (Dex), a synthetic 
GC on MAP Kinase pathways and expression of MCP-1 in activated microglia as well 
as migration of microglia have been investigated using the real time RT-PCR, 
immunocytochemistry, Western blot, ELISA and in vitro chemotaxis assay. The 
results indicate that Dex suppressed the mRNA and protein expression of MCP-1 in 
activated microglia resulting in inhibition of microglial migration. This has been 
further confirmed by the chemotaxis assay which showed that Dex or MCP-1 
neutralization with its antibody inhibits the microglial recruitment towards the 
conditioned medium of LPS-treated microglial culture.  
  This study also revealed that the downregulation of the MCP-1 mRNA 
expression by Dex in activated microglial cells was mediated via MAPK pathways. It 
has been demonstrated that Dex inhibited the phosphorylation of JNK and p38 MAP 
kinases as well as c-jun, the JNK substrate in microglia treated with LPS. The 
involvement of JNK and p38 MAPK pathways in induction of MCP-1 production in 
activated microglial cells was confirmed as there was an attenuation of MCP-1 protein 
release when microglial cells were treated with inhibitors of JNK and p38. In addition, 
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 xix
Dex induced the expression of MAP kinase phosphatase-1 (MKP-1), the negative 
regulator of JNK and p38 MAP kinases in microglial cells exposed to LPS. Blockade 
of MKP-1 expression by triptolide enhanced the phosphorylation of JNK and p38 
MAPK pathways and the mRNA expression of MCP-1 in activated microglial cells 
treated with Dex.  
 In brief, Dex inhibits the MCP-1 production and subsequent migration of 
microglial cells to the inflammatory site by regulating MKP-1 expression and the p38 
and JNK MAPK pathways. This study reveals that the MKP-1 and MCP-1 as novel 
mediators of biological effects of Dex may help developing better therapeutic 
strategies for the treatment of patients with neuroinflammatory diseases. 
  Retinoic Acid inhibits neuotoxic effect and proliferation of microglia: 
Retinoic acid (RA), the biologically active form of vitamin A, exhibits 
anti-proliferatory and anti-inflammatory activities in various cell types (Mathew and 
Sharma 2000). It has also been demonstrated that RA is synthesized in the adult 
vertebrate brain (Dev et al. 1993;Zetterstrom et al. 1999). In view of these 
observations, it is hypothesized that RA may modulate the inflammatory response 
and proliferation index of microglia. Hence, we have investigated the effects of RA 
on release of proflammatory cytokines and proliferation in activated microglia using 
immunocytochemistry, Western blot, and ELISA. It has been shown that RA could 
inhibit microglial activation by suppressing their secretions of TNF-α as well as NO 
in primary microglia cultures exposed to LPS. This inhibition of TNF-α and NO 
syntheses by RA in the activated microglia appeared to be mediated via inhibition of 
Summary 
 xx
NF-κB translocation which could be caused by upregulation of RAR and TGF-β1 
gene expression. It has also been shown that RA could inhibit syntheses of TNF-α 
and NO in activated microglia by MKP-1-mediated inhibition of JNK MAP kinase 
pathway.  
  Moreover, this study demonstrates that RA inhibits GM-CSF induced 
microglial proliferation by altering the expression of cell cycle associated proteins 
such as cyclin D1, E2F transcription factor 1 (E2F-1), Retinoblastoma (Rb) and p27. 
Based on the results, it is suggested that RA could be considered a potential 
therapeutic agent that may inhibit the expansion and activation of microglia in the 
neurodegenerative diseases. However, careful evaluation is needed before RA is 
considered for the treatment of neurodegenerative diseases as it modulates a wide 
variety of biological processes including proliferation, differentiation and apoptosis 















The central nervous system (CNS) consists of neurons and glial cells 
including astrocytes, oligodendrocytes and microglia. Microglia were first 
recognized in the brain by Nissl in 1899 (Nissl 1899) and constitute about 5-12% 
of the total glial population (Ling and Leblond 1973). They play an important role 
as resident immune cells in the healthy and diseased CNS. It is generally agreed 
that microglia are related to monocytes and belong to the mononuclear phagocyte 
lineage (Vilhardt 2005). Microglia display considerable phenotype heterogeneity 
during their life cycle such as ameboid, ramified and reactive microglia (Kaur and 
Ling 1991). Ameboid microglia found in the developing brain are phenotypically 
similar to reactive microglia found in the pathological conditions, both of which 
have a large spherical body and short processes. During postnatal stages of 
development, the ameboid microglia transform into resting ramified microglia 
which are distributed ubiquitously throughout the nervous system including the 
optic nerve and retina (Nissl 1899；Kaur et al. 2006b). When ramified microglia 
are activated in pathological conditions, they transform into ameboid morphology. 
Concurrently, they acquire functions such as induction of inflammation, 
phagocytosis and antigen presentation to circulating T cells in order to mobilize 
the defence system in the CNS (Aloisi 2001, Vilhardt 2005). Besides serving as 
resident immune cells in the brain, microglia also interact dynamically with 





1.1 Origin of microglia 
Despite intense study, the precise tissue origin and cell lineage of microglia 
are still at the centre of debate. Unlike astrocytes, oligodendrocytes and neurons, 
which are believed to be derived from neuroectoderm, microglia have been 
considered to have originated from (i) neuroectoderm, (ii) peripheral 
mesodermal/mesenchymal tissues, or (iii) from circulating blood monocytes 
(Chan et al. 2007).  The view that is widely accepted by many is the latter - that 
microglia are derived from circulating mesodermal hematopoietic cells which in 
mammals originate from the yolk sac (Chan et al. 2007). It has been demonstrated 
that circulating monocytes or precursor cells of the monocyte-macrophage lineage 
invade the developing brain during embryonic, fetal or postnatal stages (Kaur et al. 
2001) and transform into microglial cells which express several proteins, specific 
for cells of the monocyte/macrophage lineage (Kaur et al. 1984; Kaur and Ling 
1991; Ling and Wong 1993). These findings, together with the phagocytic activity 
of microglia suggest that microglia are derived from circulating monocytes and 
belong to the mononuclear phagocytic system.  
 
1.2 Functions of microglia  
In the developing brain, ameboid microglia phagocytose, the cells 
undergoing apoptosis, and are also actively involved in the determination of cell 
fate (elimination /survival) (Vilhardt 2005). In the adult brain, ramified resting 
microglia serve as supportive glial cells and their phagocytic functions are 
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downregulated. However, upon stimulation, the ramified microglia undergo a 
series of morphological and functional changes in order to respond specifically 
and appropriately towards the insult by induction of inflammation, tissue repair, 
neurotropic support, or activation of lymphocyes. The upregulation of multiple 
immunological functions is referred to as activation and is paralleled by both 
morphological transformation and discrete temporal changes in gene expression 
(Vilhardt 2005).        
    
1.2.1 Phagocytosis 
As macrophages of the CNS, the phagocytic capacity of microglia is well 
demonstrated. Microglia are capable in displaying a phagocytotic response to 
β-amyloid (Aβ) (Wilkinson et al. 2006), degenerated myelin (Makranz et al. 
2006), fibrillar prion peptide (Ciesielski-Treska et al. 2004), and apoptotic and 
nonapoptotic damaged cells (Petersen and Dailey 2004). Microglial interaction 
with these macromolecules and damaged cells is mediated through an ensemble of 
cell surface receptors, and thus pevents their harmful effects.  
  
1.2.2 Release of cytokines and chemokines 
Cytokines and chemokines secreted by microglia constitute microglial 
communication and effector system. Microglial cytokines and chemokines 
regulate innate defense mechanisms, help the initiation of immune responses, 
participate in the recruitment of leukocytes into the CNS, and support tissue repair 
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and recovery (Hanisch 2002). 
Tumor necrosis factor-α (TNF-α) is one of the major proinflammatory 
cytokines with pleiotropic functions produced by microglia as well as 
blood-derived macrophages during CNS inflammation. In microglia culture, 
synthesis and release of TNF-α is induced by pathogens or pathogen components 
(such as lipopolysaccharide (LPS) and interferon- γ (IFN-γ)). TNF-α has been 
implicated in the development of CNS inflammation mainly through their ability 
to induce expression of chemokines and adhesion molecules in cerebrovascular 
endothelial cells and astrocytes, which help leukocyte extravasation into the CNS 
(Lee and Benveniste 1999).  
Chemokines are chemotactic cytokines which act through G-protein-coupled 
receptors. Chemokines could participate in directing microglia recruitment to 
injured CNS sites and sustain their activation, whereas chemokines produced by 
microglia are likely to contribute to leukocyte recruitment and amplification of 
CNS inflammation. Chemokines promote migration of microglia to a particular 
site in the brain during development and disease processes. In conjunction with 
integrins and endothelial cell-adhesion molecule, chemokines are believed to 
control the circulation of macrophages, leukocytes and other immune cells 
(Ambrosini and Aloisi 2004). A variety of inflammatory chemokines and 
chemokine receptors have been described in the brain during disease processes.  
Glial cells stimulated by LPS and inflammatory cytokines, TNF-α and IL-1 
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(interleukin-1), in vitro have been shown to produce several chemokines such as 
macrophage inflammatory protein-1α (MIP-1α), macrophage inflammatory 
protein-1β (MIP-1β), MCP-1, IL-8 and RANTES (regulated upon activation, 
normal T cell expressed and secreted) ( Lokensgard et al. 1997; Peterson et al. 
1997; Ehrlich et al. 1998; Lipovsky et al. 1998; McManus et al. 1998). Microglia 
in culture also express chemokine receptors, CCR3, CCR5 (He et al. 1997), 
CXCR4 (chemokine (C-X-C motif) receptor 4)(Lavi et al. 1997) and CX3CR1 
(chemokine (C-X3-C) receptor 1) (Nishiyori et al. 1998).  
Among chemokines, monocyte chemoattractant protein-1 (MCP-1, also 
known as CCL2), a member of β-chemokine subfamily, mediates the migration of 
microglia, monocytes and lymphocytes to the inflammation sites in the CNS 
(Cross and Woodroofe 1999;Taub et al. 1995;Gunn et al. 1997;Babcock et al. 
2003) and is produced mainly by astrocytes and microglia (Hayashi et al. 1995). 
The MCP-1 acts on its targets by binding to its receptor, chemokine (C-C motif) 
receptor 2 (CCR2) which is a seven-transmembrane domain G-protein coupled 
receptor. The expression of MCP-1 and CCR2 has been shown to be induced 
following diverse CNS insults, including ischemia (Che et al. 2001; Minami and 
Satoh 2003; Vilhardt 2005), Alzheimer’s Disease (AD) (Fenoglio et al. 2004), 
HIV type-1-associated dementia (HAD)(Conant et al. 1998), multiple sclerosis 
and its animal model experimental autoimmune encephalomyelitis (EAE) 
(Sorensen et al. 1999; Simpson et al. 1998; Glabinski et al. 2003). In an EAE 
animal model, MCP-1 induced the recruitment and activation of endogenous 
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microglia and blood-derived macrophages to demyelinated areas, promoting 
myelin phagocytosis (Ambrosini and Aloisi 2004) . Moreover, the functional 
antagonism of MCP-1 attenuates leukocyte infiltration and decreases the severity 
of CNS injury (Calvo et al. 1996; Muessel et al. 2002). In a murine stroke model, 
MCP-1 deficiency has been shown to have a protective role in acute infarct 
growth (Hughes et al. 2002).  
 
1.2.3. Release of proteases  
Activated microglia produce a number of proteases, which contribute to 
various events in the CNS through proteolysis (Nakanishi 2003). These proteases 
include cathepsin, endosomal/lysosomal proteases, tissue-type plasminogen 
activator, and matrix metalloproteases, etc. They have been shown to play 
important roles in the MHC class II-mediated antigen presentation, processing of 
pro-inflammatory cytokines and microglia activation (Deussing et al. 1998; 
Chauvet et al. 2001; Kakimura et al. 2002) . Some members of proteases are also 
involved in neuronal death and clearance of phagocytosed Aβ peptides (Flavin et 
al. 2000; Hamazaki 1996).  
 
1.2.4 Generation of reactive oxygen species (ROS) and nitrogen intermediates 
Microglia can produce ROS when activated by various stimuli. NADPH 
oxidase (nicotinamide adenine dinucleotide phosphate-oxidase), which catalyses 
the production of superoxide from the oxygen, is implicated as the primary source 
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of microglial-derived extracellular ROS (Babior 2000). In addition to the 
production of extracellular ROS, NADPH oxidase is also thought to be a crucial 
component of microglial signalling (Babior 2000; Block et al. 2007). NADPH 
oxidase-generated intracellular ROS can act as second messenger to amplify the 
pro-inflammatory function through effects on kinase cascades and transcription 
factor activation (Block et al. 2007). However, high levels of intracellular ROS 
might result in microglial death (predominantly by apoptosis) (Sim et al. 2005). 
The overeactivation of NADPH oxidase and the dysregulation of intracellular 
ROS in microglia are associated with neurodegenerative diseases such 
Alzheimer’s Disease (AD) (Shimohama et al. 2000). 
NO,  which is produced by the action of nitric oxide synthase (NOS), 
possesses a diverse array of physiologic functions, such as muscle relaxation, 
immune modulation, and neuronal activity (Grisham et al. 1999). As a free radical, 
NO is one of the major contributors to the formation of reactive nitrogen species. 
On the other hand, NO directly reacts with poteins, especially heme-containing 
enzymes, such as guanylate cyclase, cytochrome P450, cyclooxygenase, and 
hemoglobin, to modulate their functions. In addition, NO can react with 
membrane lipids and induce lipid peroxidation. Indirectly, the combination of NO 
and superoxide can form highly reactive intermediates, such as peroxynitrite, that 
can induce DNA strand breaks, lipid peroxidation, and protein nitration (Beckman 
1996). The reactive microglia in neurodegenerative diseases produce an increased 
amount of NO, which either directly or through its highly toxic derivative, 
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peroxynitrite augments neurotoxicity in the CNS (Possel et al. 2000). Inducible 
NOS, which is a calcium independent enzyme, catalyzes the production of NO. 
Several proinflammatory cytokines have been shown to induce iNOS expression 
(Knerlich et al. 1999). 
1.2.5 Migration 
A rapid increase in number of microglial cells at injury sites is partly resulted 
from recruitment from other CNS regions by chemotaxis. The migration of 
microglia is regulated by chemokines, which are small, basic proteins produced 
during injury and infection (Ambrosini and Aloisi 2004). Under resting conditions 
in vitro, microglia have perinuclear distribution of actin and tubulin and lack 
membrane localization of these proteins and process formation (Eugenin et al. 
2005). When cells are treated with a chemotactic stimulus, rearrangement of actin 
and tubulin occurs to facilitate the process of attachment, protrusion and traction 
that allows microglia to migrate (Eugenin et al. 2005). Chemokine receptors can 
also be redistributed to the leading edge when microglia acquire a migratory 
phenotype (Eugenin et al. 2005).  Chemokines orchestrate chemotaxis as a 
protective response to injury, however, the recruited cells can also have harmful 
consequences by promoting toxicity (Ambrosini and Aloisi 2004). 
 
1.2.6 Upregulation of antigen-presentation cell (APC) capabilities 
Antigen presentation is the critical event involved in the generation of T-cell 
responses against infectious agents or against self-components (Aloisi 2001). It 
requires interaction between the T-cell receptor and processed antigen peptides 
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bound to major histocompatibility complex (MHC) molecules on the surface of 
APC (Aloisi 2001). Microglial cells behave as poor APCs in their resting 
condition since the ability to present antigens to T cells is inhibited in the normal 
CNS (Bailey et al. 2006). However, microglia upregulate MHC-II expression in 
virtually all inflammatory and neurodegenerative conditions (Kreutzberg 1996). 
Microglial cells in these pathological conditions are able to take up, process, and 
present protein antigen to naive, memory, and differentiated T cells, leading to 
either T cells proliferation, cytokine secretion or both (Becher et al. 2000).  
 
1.2.7 Proliferation 
One of the main characteristic features of microglial cell population is their 
remarkable capacity to expand in response to injury or neurological disease 
processes (Ladeby et al. 2005). This expansion is considered predominantly to be 
due to proliferation of activated microglia and to a lesser extent migration of 
microglia from adjacent brain areas as discussed in detail before (Ladeby et al. 
2005). Indeed, proliferating microglia have been implicated in the onset and/or 
progression of a number of CNS pathology such as trauma (Urrea et al. 2007), 
ischemia (Denes et al. 2007), Parkinson’s disease (Henze et al. 2005) and 
demyelination (Remington et al. 2007). These cells which respond to injury may 
participate in brain repair and functional recovery by phagocytosis of debris; 
however, they may also contribute to glial scar formation and excess release of 
cytotoxic factors (Byrnes and Faden 2007).    
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The most likely candidates that induce and sustain microglial proliferation 
are the colony stimulating factors (CSF), including macrophage-colony 
stimulating factor (M-CSF) and granulocyte macrophage-colony stimulating 
factor (GM-CSF), both of which promote microglial proliferation in vitro as well 
as in vivo (Sawada et al. 1990; Lodge and Sriram 1996; Kloss et al. 1997; Sasaki 
et al. 2000), and are produced either by astrocytes or microglia themselves in an 
autocrine fashion (Nakajima et al. 2006). Other factors which have been shown to 
promote microglial proliferation and survival are NT-3 (Elkabes et al. 1996), IL-4 
and IL-5 (Elkabes et al. 1996). 
The mechanisms of the microglia proliferation appear to involve the 
regulation of cell cycle. The cell cycle is the series of events that can be divided 
into 4 phases:  G1 phase (Gap1 phase), S phase (DNA replication phase), G2 
phase (Gap2 phase), and M phase (mitotic phase). Progression through the cell 
cycle is controlled by the interaction of several factors including cyclins, 
cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CDKIs). 
Cyclins are key molecules in cell cycle control. Cyclin D (including D1, D2, and 
D3) forms a complex by binding with CDK4 and CDK6, and regulates the 
transition from G1 phase to S phase, which is a rate-limiting step in the cell cycle 
(Bruce et al. 2007). The best known effects of Cyclin D/CDK4,6 complex activity 
are mediated by a gene regulatory protein, E2F, which transactivates many genes 
that encode proteins required for S phase entry (Bruce et al. 2007). E2F function 
is in turn controlled by an interaction with the retinoblastoma protein (Rb), an 
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inhibitor of cell-cycle progression (Simin et al. 2004). During G1 phase, Rb binds 
with E2F and blocks the transcription of S-phase genes. When cells are stimulated 
to divide by extracellular signals, cyclin D/CDK4, 6 complexes induce 
phosphorylation of Rb, and release of E2F that activates transcription of S phase 
genes (Bruce et al. 2007). E2F-1 is one of the six members of the E2F family. 
Although E2F-1 activity is considered to be regulated mainly through its temporal 
association with Rb, recent reseach has shown a direct induction of E2F-1 by 
growth factors such as IGF-1 (Shen et al. 2004). P27 belongs to the family of 
CDKIs, is associated with a variety of cyclin-CDK complexes and inhibits their 
activity, leading to cell cycle arrest at G1/S phase (Simeone and Tari 2004). 
Although microglia in mature CNS are considered terminally differentiated, 
they can re-enter the cell cycle after stimulation (Suh et al. 2005). Expression of  
cell cycle proteins such as cyclin D1 in microglia has been shown in the 
hippocampus of ischemic rat brain (Wiessner et al. 1996). Furthermore, 
Grannulocyte-Macrophage colony stimulating factor (GM-CSF) administration 
has been shown to increase the expression of cyclin D1 and decrease the 
expression of p27 in a microglial cell line (GMI-M6-3) (Koguchi et al. 2003). 
Further understanding of mechanisms of microglial proliferation may improve 
therapeutic strategy that limits the microglial expansion and subsequent 





1.3  Microglial activation 
1.3.1. Activation of microglia by various stimuli 
Functions of microglial cells in the CNS appear to be complex as they exhibit 
both neuroprotective and neurotoxic effects. In the past decades, a large number of 
papers have focused on the understanding of mechanisms of microglial activation 
in response to neuropathological conditions in vivo and in vitro.  For in vitro 
analysis, microglial cells are activated by various inflammatory stimuli such as 
LPS, Aβ, thrombin and some proinflammatory cytokines including IFN-γ. The 
inflammatory response of activated microglia appears to be consistent although 
the nature of the stimuli varies. 
 
1.3.1.1. Lipopolysaccharide 
LPS is a cell wall component of Gram-negative bacteria and the most 
frequently used activator for microglia activation and inflammatory signaling. In 
experimental endotoxemia, LPS has been shown to enter the brain parenchyma by 
diffusion through regions with defective blood-brain barrier (BBB) function. After 
binding of LPS to LPS binding protein (LBP), its receptor CD14 presents the 
LPS-LBP complexes to Toll-like receptor 4 (TLR4) (Chen et al. 2002). Interaction 
of TLR4 with the LPS-LBP-CD14 complexes triggers a signaling cascade 
involving activation of a set of transcription factors such as NF-κB and AP-1  
(Rivest 2003). This ultimately leads to the expression of a wide array of 
inflammatory mediators including proinflammatory cytokines, chemokines and 
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ROS which orchestrate inflammation and activation of adaptive immunity to 
eliminate invading microorganisms (Lacroix et al. 1998) .  
 
1.3.1.2. β-Amyloid  
    Aβ have been widely used to activate microglial cells in vitro. Extracellular 
Aβ deposit (or senile plaques) is one of the two characteristic lesions in the brains 
of individuals with AD.  They induce the neurodegeneration both directly by 
interacting with components of the cell surface to trigger apoptogenic signaling 
and indirectly by activating microglia to produce excess amounts of inflammatory 
cytokines (Chiarini et al. 2006). Microglial cells activated with the treatment of 
Aβ1-42 or Aβ25-35 in vitro exhibit upregulation of mRNA and protein expression 
of proinflammatory cytokines, proteases and chemokines which include IL-1β, 
IL-8, IL-10, IL-12, TNF-α, MIP-1α, MIP-1β and MCP-1  (Nagai et al. 2001). 
These results indicate that reactive microglia play a significant role in the 
initiation and propagation of immune responses as the inflammatory mediators 
during the process of inflammation in neurodegenerative diseases. 
 
1.3.1.3. Interferon -   
Interferon (IFN)-  also appears to be a key cytokine in the activation of 
microglial cells (Chao et al. 1993; Xu and Ling 1994). In murine models, 
microglial cells exhibit significantly increased myelin phagocytosis, proteolytic 
enzyme secretion, and oxidative stress in response to IFN-  (Smith et al. 1998). 
Introduction 
 15
IFN-  and microglial cells are thought to play important roles in initiation and 
development of multiple sclerosis. Recently, the molecular mechanisms of human 
microglial responses to IFN-  have been studied by microarray. This microarray 
analysis which revealed a change in expression of number of genes, including 
transcriptionally induced chemokines, IFN-  signaling factors, MHC genes and 
proinflammatory T-lympocyte-related chemokine genes as well as genes involved 
in antigen presentation, provides a foundation for the molecular mechanisms of 
microglial activation by IFN-  (Rock et al. 2005). This study showed no increase 
in expression of NOS genes in response to IFN-  which is in contrast to results 
found in the murine model. This difference suggests a possible species specific 
response of microglia to IFN- . 
 
1.3.1.4. Thrombin 
In addition to its role in coagulation cascade, the serine protease thrombin 
has been shown to activate microglia through proteolytic activation of 
protease-activated receptors (PARs). Thrombin-induced microglial activation 
induces cytokine release, proliferation and intracellular calcium signaling (Moller 
et al. 2006). Further, it has been shown that thrombin activates microglia by 
inducing NADPH oxidase and oxidative stress. The thrombin-induced microglial 
activation has also been shown to result in the production of toxic and 
inflammatory mediators leading to degeneration of dopaminergic neurons and 
hippocampal neurons (Beal 2002; Koutsilieri et al. 2002; Gao et al. 2003; Wu et 
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al. 2003; Block et al. 2004; Qin et al. 2004; Choi et al. 2005; Moller et al. 2006; ). 
 
1.3.1.5. Granulocyte-macrophage colony stimulating factor and macrophage 
colony stimulating factor 
GM-CSF is a hematopoietic growth factor that promotes the survival and 
proliferation of microglia in culture. GM-CSF has numerous effects on microglia, 
ranging from induction of proliferation to changes in morphology and immune 
properties (Suzumura et al. 1990; Esen and Kielian 2007). It has been repoted that 
GM-CSF induces the expression of genes related with chemotaxis, antigen 
processing, and innate immunity, suggesting that GM-CSF helps the transition of 
microglia into a more professional antigen presenting cell phenotype (Esen and 
Kielian 2007). Activated astrocytes appear to be the main source of GM-CSF in 
the CNS (Koguchi et al. 2003) .  
Macrophage colony stimulating factor (M-CSF), a hematopoietic growth 
factor, also activates microglial cells by enhancing the microglial proliferation and 
production of inflammatory cytokines and NO (Hao et al. 2002). Increased 
M-CSF receptor expression by activated microglia has been reported after 
ischemic and mechanical brain injury in mice (Raivich et al. 1998; Wang et al. 
1999). A transient overexpression of M-CSF receptor on murine microglial cell 
lines resulted in microglial proliferation and increased expression of iNOS, 
proinflammatory cytokines, IL-1α, MIP-1α, IL-6 and M-CSF (Mitrasinovic et al. 
2001). M-CSF acts as a mitogen on microglia in vitro (Lodge and Sriram 1996; 
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Sawada et al. 1990; Kloss et al. 1997) and mutation in the M-CSF gene inhibits 
microglial proliferation in vivo (Wegiel et al. 1998; Sasaki et al. 2000), indicating 
that M-CSF expression in microglia may be one of the molecular signals that 
initiate proliferation of microglia at the injury site.   
 
 
1.3.2. Signaling pathways mediating microglial activation 
1.3.2.1. Mitogen-activated protein kinase pathways 
    Mitogen-activated protein kinases (MAPKs) are serine/threonine protein 
kinases that are highly evolutionarily conserved in eukaryotic species. MAPK 
pathways have important roles in various cellular processes, such as stress 
response, immune defence and proliferation (Liu et al. 2007). Four major MAPK 
pathways have been reported in mammals: 1) p38 MAPK; 2) 
extracellular-signal-regulated kinases (ERK1/2, also known as p44/42 MAPK); 3) 
c-jun N-terminal kinases/stress-activated protein kinases (JNKs/SAPKs); 4) ERK5 
(big MAPK1). The four MAPK signaling pathways are activated by distinct and 
sometimes overlapping sets of stimuli (Hommes et al. 2003). In general, ERKs are 
activated by growth factors, whereas the p38 and JNK are activated by stress 
stimuli (Ma et al. 2004) . 
Microglial response to extracellular stimuli is mediated by MAPK pathways. 
Several reports have demonstrated that MAPK pathways play a significant role in 
activation of microglial cells which in turn leads to release of neurotoxic 
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molecules and neuroinflammation (Lee et al. 2000; Li et al. 2001; Waetzig et al. 
2005a). In vivo evidence also implicates that MAPKs play an important role in 
microglial activation in acute brain injury such as stroke and in chronic 
neurodegenerative diseases such as AD. Recently, MAPK-activated protein kinase 
2 (MAPKAP kinase 2 or MK2), which is one of several kinases directly regulated 
by p38 MAPK,  has been shown to play a role in neuroinflammatory and 
neurodegenerative pathology by inducing release of pro-inflammatory mediators 
in microglial cells (Culbert et al. 2006). The activation of MK2 expression was 
increased in microglial cells stimulated by LPS and IFN-γ, implicating a role for 
MK2 in eliciting a proinflammatory response of microglial cells. 
Activation of these MAPK pathways leads to induction of a wide array of 
downstream targets, including protein kinases and nuclear transcription factors, 
which lead to transcription of MAPK-regulated genes. AP-1, a member of the 
basic region-leucine zipper (bZIP) family of DNA binding proteins, is one of the 
downstream targets of MAPK pathways. AP-1 is comprised of a Jun family 
member (c-Jun, v-Jun, Jun-B, or Jun-D) homodimerized with another Jun protein 
or heterodimerized with a Fos protein (c-Fos, Fos-). LPS has been shown to 
stimulate the dimerization via c-Jun phosphorylation by JNK (Smoak and 
Cidlowski 2004).  
The MAPK pathways can be regulated by various mechanisms. One of the 
most efficient ways of deactivation is dephosphorylation of the kinases by 
phosphatases. A number of protein phosphatases has been discovered, including 
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MAPK phosphatase-1 (MKP-1). MKP-1 is a prototype of dual specificity 
phosphatase induced by cellular stresses, serum and growth factors and 
dephosphorylates MAP Kinases such as  JNK,  p38, and also ERK1/2 in some 
circumstances (Clark 2003).  
 
 
1.3.2.2. Nuclear factor-κB pathway 
Nuclear factor-κB (NF-κB) is a ubiquitous transcription factor whose 
involvement in microglia activation is well established in both in vitro and in vivo 
experimental systems (Quan et al. 2000; Nakamichi et al. 2007). NF-κB consists 
of homodimers or heterodimers assembled from subunits including p65 (Rel A), 
c-Rel, Rel B, p52/p100, and p50/p105. The p65/p50 heterodimer is the 
prototypical and most thoroughly studied NF-κB dimer (Baeuerle and Henkel 
1994). NF-κB is latently present in the cytoplasm, under control of the associated 
protein I-κB. The first step in the activation of NF-κB is an I-κB kinase complex 
(IKK)-dependent phosphorylation of I-κB, followed by ubiquitinylation and 
degradation. This finaly leads to release of the NF-κB protein which is 
translocated to the nucleus to exert its effects on gene regulation (Brasier 2006).  
 
1.3.3. Microglia activation in brain disorders 
It has been widely demonstrated that microglial cells are activated in 
neurodegenerative diseases such as AD, PD and Creutzfeldt-Jakob disease (CJD), 
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MS, HIV-associated dementia (HAD) and stroke.  In these diseases, only resident 
microglial cells respond to inflammation in the absence of neutrophil infiltration 
and mononuclear cell perivascular cuffing. These microglial cells rapidly 
proliferate, become hypertrophic and express a plethora of marker molecules such 
as the macrophage antigen complex-1 (MAC-1), the cytotoxic molecules 
including ROS, NO and a variety of proinflammatory cytokines such as TNF-α, 
IL-1β. Although several reports indicate that the chronic inflammation could 
influence the pathogenesis of degenerative diseases, the potential detrimental or 
protective roles of activated microglial cells in these diseases remain to be 
elucidated.  
 
1.3.3.1 Alzheimer’s disease 
AD is the most common neurodegerative disorder of the elderly, and it is 
characterized clinically by progressive memory loss, as well as other cognitive 
impairments. The neuropathological hallmarks of AD include abundant deposits 
of Aβ fibrils as senile plaques (SPs), massive accumulations of abnormal tau 
filaments (one type of mirotubule associated proteins) and intraneuronal 
neurofibrillary tangles (NFTs), and extensive neuronal degeneration associated 
with profuse reactive microglia. Apart from the SPs and NFTs, AD brains also 
exhibit a number of nondiagnostic pathological abnormalities, including a 
profound loss of synapses, massive neuronal degeneration, extensive gliosis, 
microglial proliferation/activation, and evidence of an unusual inflammatory 
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process (Clark and Trojanowski 2000). 
Microglia activation is associated with the neuropathology of AD. It has been 
reported that Aβ-42 is far more toxic to neurons in vitro when they are cocultured 
with microglia (Qin et al. 2002). Moreover, cytokines produced by activated 
microglia can both stimulate neuronal production of amyloid precursor protein 
(APP), and promote its conversion to Aβ (Ge and Lahiri 2002). This suggests a 
vicious cycle in which neural production of Aβ leads to microlglia activation, 
which in turn promotes neuronal cell death while further stimulating Aβ 
production (Blasko et al. 2004).  
 
1.3.3.2. Parkinson’s disease  
PD is the second most common aging-related neurodegenerative disease after 
AD. PD is clinically characterized by various symptoms including tremor, 
slowness of movement, stiffness and postural instability (Fahn and Przedborski 
2000). These symptoms are primarily attributable to the degeneration of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the 
consequent loss of their projecting nerve fibres in the striatum (Hornykiewicz and 
Kish 1987; Pakkenberg et al. 1991). The disease is suggested to be caused by 
some exogenous or endogenous substances that are neurotoxic to catecholamine 
neurons, which lead to mitochondrial dysfunction and subsequent oxidative stress 
resulting in the apoptosis of dopaminergic neurons. In addition to the 
neurodegeneration in SNpc, there is a robust microglial reaction which 
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accompanies an inflammatory process in PD and experimental models of PD. The 
activated microglial cells which produce protective or toxic substances, such as 
cytokines including TNF-α and IL-6 proteins, neurotrophins, and ROS may be 
neuroprotective in the initial stage, and later become neurotoxic due to toxic 
change resulting in the death of CA neurons ( Mogi et al. 1994b; Mogi et al. 
1994a; Imamura et al. 2003; Nagatsu and Sawada 2006) 
 
1.3.3.3. Multiple sclerosis  
   MS is one of the most common CNS diseases characterized by inflammatory 
reaction, demyelination and axonal loss in the brain, spinal cord and optic nerve 
(Sanders and De 2007). It is an autoimmune disorder and the acquired immune 
system plays a central role in the pathogenesis of MS although target antigens and 
effector mechanisms are still poorly defined (Hemmer et al. 2004).  Microglia 
participate in nearly all phases of the disease process, including recognition of 
stranger/danger signals, presenting antigens to cells of the adaptive immune 
system and inducing an inflammatory response (Jack et al. 2005) . Modulation of 
the dynamic properties of microglia so as to limit potential damaging innate 
response remains a therapeutic challenge (Jack et al. 2005).  
 
1.3.3.4. HIV associated dementia 
In recent years, considerable attention has been drawn to the factors 
involved in the development of HIV associated dementia (HAD) which is 
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characterized by cognitive, behavioral, motor deficits ranging from mild disease to 
profound dementia. The primary factor in the development of HAD is the 
infection of mononuclear phagocytes and microglial cells with HIV-1. The HIV-1 
infected microglial cells and macrophages are activated and secrete both 
endogenous neurotoxins such as TNF-α, IL-1ß, IL-8, eicosanoids and NO as well 
as neurotoxic viral proteins such as Tat, gp120 and gp41 (Brenneman et al. 1988; 
Nottet et al. 1995; New et al. 1997). These microglial cells can also induce the 
recruitment of additional microglia and macrophages to the site of infection by 
inducing endothelial cells to release chemokines such as MCP-1, MIP-1α and 
MIP-1ß (Lipton and Gendelman 1995; Persidsky et al. 1999; Nelson et al. 2002). 
Overall, microglial cells are the principal target of HIV-1 in the brain and the 
activated microglial cells contribute significantly to the HIV-1 associated 
neuropathogenic processes (Nelson et al. 2002). 
The prevalence of neurodegenerative diseases is increased with aging. 
Ageing seems to influence microglial activation that could contribute to an 
enhanced inflammatory response in the brain, leading to neurodegenerative 
diseases. Aged brains in rodents and human show increased numbers of activated 
phagocytic microglia and increase in IL-1β, OX42 and OX6 expressing microglial 
cells (Rozovsky et al. 1998; Sheng et al. 1998; Conde and Streit 2006). The 
age-related activation of microglia appears to be a reflection of a lifelong 
accumulation of minor insults, leading to an increased risk of neurodegenerative 
diseases. In addition, several recent reports demonstrate that microglial cells are 
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subjected to age-related structural deterioration and cellular senescence, which 
may be caused by various factors including genetic and epigenetic alterations and 
cellular accumulation of Aβ protein ( Korotzer et al. 1993; Flanary and Streit 2004; 
Streit et al. 2004). This raises the possibility that microglial cells may become 
increasingly dysfunctional with ageing, thereby their normal neuroprotective 
functions are decreased, resulting in the increased risk of neurodegenerative 
diseases in aged population (Streit 2006). 
 
1.4. The role of microglia during neurogenesis and synaptogenesis in the 
brain 
Neurogenesis is a life-long process which occurs in the developing and 
adult brain. In the adult brain, the hippocampus is the unique structure which 
produces new neurons throughout adult life since it contains a population of 
neural stem cells.  Inflammation and activation of microglia by irradiation in the 
brain has been shown to impair the hippocampal neurogenesis (Ekdahl et al. 
2003).  In addition, neurogenesis was found to be inhibited when neural stem 
cells were exposed to activated microglia in vitro (Kempermann and Neumann 
2003). In view of these findings, it was suggested that activated microglial cells 
could play a significant role in inflammation-induced impairment of neurogenesis 
in the hippocampus. Proinflammatory mediators released by microglia appear to 
be important contributing factors to the block in neurogenesis since treatment with 
non steroidal anti-inflammatory drugs restores hippocampal neurogenesis (Monje 
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et al. 2003) . However the exact mechanisms by which microglial activation 
impairs the neurogenesis in the adult brain are not clear and need to be explored.  
Apoptosis which is a prominent feature during early neural tube 
development, occurs in the cells of developing brain vesicles on days 10 and 11 of 
gestation in order to halt premature neurogenesis (Akazawa, 2005). Several 
studies show that microglia invade neural tissue shortly before or concomitantly to 
the period of naturally occurring neuronal death and induce apoptosis in 
developing neurons via the release of diffusible factors such as nerve growth 
factors and superoxide ions (Frade and Barde 1998;Marin-Teva et al. 2004). These 
observations indicate potential role of microglia on cell fate specification during 
neurodevelopment. However, it should be further clarified in vivo as most of these 
results are based on in vitro studies. 
Microglia have also been shown to be involved in developmental 
synaptogenesis. They invade the developing neural tube in embryos, increase in 
number significantly during first week of postnatal stage through P18 (Dalmau et 
al. 1998; Dalmau et al. 2003), the period when intense synaptogenesis occurs. In 
the developing brain, microglia express thrombospondins, a family of 
extracellular matrix proteins which induce synaptogenesis (Christopherson et al. 
2005).  Moreover, microglial activation followed by neuronal death has been 
shown to be associated with synaptogenesis in experimental axotomy as they 
secrete thrombospondins (Chamak et al. 1995; Moller et al. 1996; Moran and 
Graeber 2004). Microglia express a broad spectrum of cytokines, neurotrophins 
Introduction 
 26
and other molecules such as glutamate and NO which regulate synaptic functions. 
 These results support the notion that microglia could regulate synaptogenesis 
and neuronal apoptosis, indicating a strong functional bond between neurons and 
microglia. Overall, it is fairly well demonsrated that microglia regulate several 
aspects of neuronal functions in normal and pathological conditions and are 
activated by neurodegeneration. However, the interaction between microglia and 
non-neuronal cell types including oligodendrocytes and astrocytes has not yet 
been investigated systematically. Systematic investigation on functional 
interaction between microglia and neuronal and non-neuronal cell types including 
oligodendrocytes and astrocytes in vivo would greatly help in the understanding 
how the brain functions in normal and pathological conditions. 
  
1.5. Inhibition of microglial activation may improve therapeutic strategy for 
neurodegenerative diseases 
Neurodegerative diseases share certain common features such as microglial 
activation associated with excitotoxic neuronal death and dysfunction. There is a 
vicious cycle in which the neuronal death leads to microglial activation, which in 
turn promotes death and dysfunction of neurons. Hence, measures which inhibit 
microglial activation may have a favorable effect on the induction and progression 
of neurodegenerative diseases, independent of the particular trigger or target 
involved in a given disorder (McCarty 2006). Consistent with this possibility, 
some inhibitors of microglia activation may have potential to be used in the 
Introduction 
 27
therapy of neurodegenerative disorders.    
  Although several drugs alleviate symptoms of neurodegenerative diseases, 
chronic use of these drugs is often associated with debilitating side effects, and 
none seems to dampen the progression of these diseases. So far, the development 
of effective neuroprotective therapies is impeded by our limited knowledge of the 
pathogenesis of neurodegenerative diseases. Several studies have demonstrated 
that the inhibition of microglial activation may help development of better 
therapeutic strategies for neurodegenerative diseases. 
 
1.5.1. Glucocorticoids 
Glucocorticoids (GCs) are the most powerful endogenous 
immunosuppressors for the innate immune response and the subsequent 
inflammatory reaction (McKay and Cidlowski 1999). GCs exert their actions by 
binding to an intracellular GC receptor, a ligand-activated transcriptional regulator 
that belongs to the nuclear receptor superfamily (Schoneveld et al. 2004). 
Blockade of endogenous GCs exacerbates the LPS-induced inflammatory 
response leading to neurotoxicity in the rat brain (Nadeau and Rivest 2003).  
Dexamethasone (Dex), a potent anti-inflammatory and immunosuppressive 
glucocorticoid, is widely used in the treatment of inflammation and a number of 
autoimmune disorders (Wilckens and De 1997). The immuno-suppressive 
properties of GCs have been ascribed to their ability to suppress the synthesis of a 
number of cytokines including IL-12p40 (Ma et al. 2004). GCs have been shown 
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to mediate their biological effects on cytokine production in LPS stimulated 
monocytic cells primarily by down regulating MAPK activation as well as AP-1 
and NF-κB activity ( Jonat et al. 1990; Schule et al. 1990; Anuphan N et al. 1995; 
Scheinman RI et al. 1995; Blotta MH et al. 1997; Hirasawa N et al. 1998; 
Franchimont 2000; Steer et al. 2000; Yang-Yen et al. 1990). Several lines of 
evidence suggest that GCs induced sustained expression of  MKP-1  in various 
cell lines such as Hela cells (Lasa et al. 2002), osteoblasts (Engelbrecht et al. 
2003), macrophages (Roger et al. 2005) and epithelial cells (Imasato et al. 2002; 
Sakai et al. 2004). As MKP-1 is a negative regulator of MAPK pathway, action of 
GCs on MAPK pathway appears to be mediated via MKP-1 expression. 
It is well known that activation of AP-1 and NF-κB nuclear translocation is 
transcriptional activation of most proinflammatory genes. GCs also appear to act 
on microglial proliferation as the number of microglial cells was found to be 
reduced significantly in the developing corpus callosum following Dex treatment 
(Kaur et al. 1994). However, GCs are known to produce various side effects; 
hence, it is suggested that studies on its downstream targets may yield a better 
clinical outcome. 
 
1.5.2. Retinoic acid 
    Retinoic acid (RA, a vitamin A metabolite) plays essential roles in cell 
growth, differentiation and apoptosis. Besides that, several lines of evidence 
suggest that RA exerts an anti-inflammatory effect and attenuates the production 
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of inflammatory mediators such as TNF- α  and iNOS in various cell types (Datta 
et al. 2001). It is well known that RA modulates the target cell activity by binding 
to one of its two receptors: retinoic acid receptors (RAR)-α, -β, -γ and retinoid X 
receptors (RXR)-α, -β, -γ, both of which are members of the steroid hormone 
receptor superfamily (Simeone and Tari 2004). RAR or RXR may modulate gene 
transcription by binding directly to promoters containing a RA receptor element 
(RARE) or via antagonistic cross-coupling of transcription factors such as NF-κB 
(Xu et al. 1997). Recent studies have demonstrated the synthesis of RA in the 
adult vertebrate brain (Dev et al. 1993; Zetterstrom et al. 1999). In the human 
brain, retinaldehyde dehydrogenase (RLDH), the enzyme that forms RA from 
retinaldehyde, has been shown to be present in the hippocampus, and the frontal 
and parietal cortex (Connor and Sidell 1997). Its function in control of growth and 
differentiation in the embryonic CNS as well as neuroral plasticity and 
neurogenesis in the adult CNS has been extensively investigated (McCaffery et al. 
2006). However, its effects on microgilal proliferation and their release of 
proinflammatory mediators have not been fully understood.  
 
1.5.3. Minocycline 
Minocycline, a semisynthetic tetracycline derivative,  exhibits 
neuroprotective effects in neurodegenerative diseases including PD, Huntington’s 
disease, amyotrophic lateral sclerosis, focal and global ischemia and traumatic 
brain injury (TBI) (Chen et al. 2000;He et al. 2001;Sanchez Mejia et al. 
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2001;Yrjanheikki 1998;Yrjanheikki 1999).  It has been shown to inhibit 
microglial activation in various pathological conditions by suppressing the ROS 
production and expression of proinflammatory cytokines (Amin et al. 1996; 
Yrjanheikki  1998; Yrjanheikki  1999; Tikka  2001; Tikka and Tikka 2001). In 
the mouse model of PD, minocycline mitigates the loss of dopaminergic cell 
bodies in the SNpc and of nerve terminals in the striatum, prevents microglial 
activation and reduces the synthesis of IL-1β. Minocycline has also been shown to 
inhibit the thrombin-induced microglial activation together with the upregulation 
of iNOS and NADPH-oxidase, two enzymes implicated in microglial derived 
production of NO and ROS, respectively (Cai et al. 2001; Du  2001; Wu et al. 
2002; Choi et al. 2003; Choi et al. 2005). Recently, it has been further shown that 
minocycline inhibits retinal microglia activation in retinal neurodegenerative 
diseases by suppressing the production of inflammatory cytokines and NO (Wang 
et al. 2005). 
 
1.5.4. Vitamin D 
There is accumulating evidence suggesting an involvement of various 
vitamins in brain functions and anti-inflammatory processes in CNS injuries. 
vitamin E, a powerful biological anti-oxidant, has been shown to play 
neuroprotective roles by preventing the free radical-induced neurotoxicity and 
suppressing microglial activation (Kamal-Eldin and Appelqvist 1996). The 
vitamin E-induced inhibition of microglial responses to LPS was correlated with 
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the suppression of the activation of p38 MAPK and NFκB, both of which regulate 
cytokine and iNOS expression (Lee et al. 1994). Vitamin D also exhibits 
immunomodulatory properties via its specific receptor, vitamin D3 receptor 
expressed in antigen-presenting cells, activated lymphocytes and microglia in the 
CNS ( Lemire 2000; Lefebvre et al. 2003). It has direct anti-inflammatory effects 
on activated microglia by inhibiting the production of TNF-α, IL-6 and NO 
(Lefebvre et al. 2003). 
 
1.5.5. Endocannabinoids 
The cannabinoids, which are active components of Cannabis sativa 
(marijuana) have been shown to protect neurons from toxic insults such as 
excitotoxicity, traumatic injury and ischaemia both in vitro and in vivo 
(Mechoulam et al. 2002; van der et al. 2002). Recently it has been shown that the 
endocannabinoid system consisting of cannabinoid receptors such as CB1 and 
CB2, their endogenous ligands, enzymes for synthesis and degradation of 
endocannabinoids, is highly activated during CNS inflammation and the signaling 
of endocannabinoid suppresses microglial activation by inducing histone H3 
phosphorylation, MKP-1 gene expression and subsequent ERK-1/2 
dephosphorylation which in turn abolishes NO release resulting in neuroprotection 
( Hansen et al. 2001; Panikashvili et al. 2001; Marsicano et al. 2003; 
Eljaschewitsch et al. 2006b). These findings have led to a remarkable expansion 
of basic cannabinoid research which would enhance the therapeutic value of 
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TGF-β1 has been considered as a potent anti-inflammatory cytokine and 
plays a pivotal role in maintaining balanced host responses in inflammatory and 
immunological conditions in the CNS (Letterio and Roberts 1998). Activation of 
microglia by brain ischemia, proinflammatory factors, LPS and Aß leads to 
increased production of TGF-ß1 that may counteract the proinflammatory 
reactions ( Constam et al. 1992; Weissner et al. 1993; Chao et al. 1995; Dheen et 
al. 2005). Several studies have demonstrated the potential mechanism and 
signaling pathway for the repressive effect of TGF-ß1 on overactivation of 
microglial cells.  It has been reported that TGF-β1 suppresses microglial 
activation via inhibition of phosphatidylinosotol 3-kinase (PI3K) activity and its 
downstream signaling molecules by inhibition of formyl peptide receptor like 2 
(FPR2) expression through Smad-3 mediated pathway (Kim et al. 2004; Le et al. 
2004). In experimental AD models, FPR2 mediates the proinflammatory activity 
of Aβ in mononuclear phagocytes which result in the release of neurotoxic 
effectors. These data indicate that the cross-talk between TGF-β1 and PI3K 
/Smad3/MAPK signaling pathways may be important therapeutic targets for 




1.5.7. Chondroitin sulfate proteoglycan 
Chondroitin sulfate proteoglycan, a matrix protein that occurs naturally in the 
CNS has been shown to participate in the activation of inflammatory response. 
Recently it has been shown that the disaccharidic degradation product of this 
proteoglycan modulates the inflammatory responses and markedly alleviates the 
clinical symptoms of immune-induced neuropathologies of the CNS such as EAE 
(Rolls et al. 2006). This effect was associated with a reduction in numbers of 
infiltrating T cells, marked microglial activation, decreased secretion of cytokines, 
TNF-α and decreased expression of NF-κB, suggesting that a compound degraded 
from an endogenous CNS-resident molecule may provide a potential therapeutic 
modality for inflammation-induced neurodegenerative diseases. 
 
1.5.8. PPARγ agonists 
The peroxisome proliferators-activated receptor γ (PPARγ) belongs to a large 
group of nuclear receptors and controls immune responses by acting as an 
agonist-activated transcription factor to regulate target gene expression (Bernardo 
and Minghetti 2006).  PPARγ is expressed in primary microglia cultures and its 
agonists have been shown to downregulate microglia activation, by inhibiting  
TNF-α synthesis, MHC class II expression, and by inducing apoptosis which may 
contribute to the safe elimination of activated microglia (Bernardo et al. 2000; 
Bernardo et al. 2003). Although a majority of the data are derived from in vitro 
studies, an increasing number of studies in animal models further suggest that 
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PPARγ agonists can provide therapeutic benefits in MS, PD and AD (Bernardo 
and Minghetti 2006).   
All the drugs and molecules described above attempt to suppress the 
neurotoxic effect of microglial cells in CNS diseases. It should be emphasized that 
the neuroinflammation in CNS diseases is amplified considerably by the rapid 
influx of microglial cells to injury sites in the CNS. The migration of microglia is 
regulated by various chemokines. Recently, it has been shown that expression of 
chemokines such as MCP-1 and IFN-γ inducible protein-10 (IP-10) by astrocytes 
plays a role in migration and activation of microglial cells and subsequent 
amplification of neurodegeneration in secondary progressive MS (Tanuma et al. 
2006) . Therefore, targeting chemokines may be one of the therapeutic options to 
inhibit neuroinflammation caused by proinflammatory cytokines released by 
activated microglial cells.  
 
1.6.  Aims of this study 
An inflammatory process in the CNS is believed to play an important role in 
the pathway leading to neuronal cell death in a number of neurodegenerative 
diseases. The inflammatory response is mediated by the activated microglia, 
which normally respond to neuronal damage and remove the damaged cells by 
phagocytosis. Activation of microglia is a hallmark of brain pathology. The 
chronic activation of microglia may in turn cause neuronal damage through the 
release of potentially cytotoxic molecules such as proinflammatory cytokines 
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including TNF-α and IL-1β, reactive oxygen intermediates, proteinases and 
complement proteins. Therefore, suppression of microglia-mediated 
inflammation has been considered as an important strategy in neurodegenerative 
disease therapy. Several anti-inflammatory drugs have been shown to repress the 
microglial activation and to exert neuroprotective effects in the CNS after 
different types of injuries. However, these drugs do not specifically target on 
microglial cells and therefore, exhibit potential systemic side effects. The purpose 
of this study was to understand the potential mechanisms and signaling pathways 
for the repressive effect of some drugs (i.e., glucocorticoids and retinoic acid)  
on activation of microglial cells in CNS diseases. The main objectives are: 
 
1.6.1. To examine the effects of Glucocorticoids on the chemotaxic activity of 
activated microglia 
GCs are widely used anti-inflammatory and immunomodulatory agents and 
inhibit expression of proinflammatory genes in various cell types (Wilckens and 
De 1997; De et al. 2003). Recently, it has been shown that GCs could inhibit 
LPS-induced MCP-1 production in the hippocampus and cortex (Szczepanik and 
Ringheim 2003; Little et al. 2006). However, the molecular mechanisms by which 
GCs regulate MCP-1 expression have not been elucidated. It has been further 
reported that GCs counter-regulate MAPK signaling pathways, in particular p38, 
and JNK pathways by inducing expression MKP-1 (Clark 2003). Activation of 
MAP kinases in microglial cells, leads to phosphorylation of transcription factors 
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such as c-Jun/AP-1 resulting in induction of expression of some target genes 
including TNF-α and MCP-1 (Babcock et al. 2003; Waetzig et al. 2005). 
Based on these data, it is hypothesized that GCs inhibit MCP-1 production 
via MKP-1-mediated inactivation of MAP kinases, resulting in decreased 
microglial migration towards the sites of inflammation in CNS. To address this,  
1. the effects of GCs on LPS-induced MCP-1 mRNA expression and protein 
release in the rat microglia of primary culture have been examined.  
2. the mechanisms by which GCs inhibit MCP-1 production in activated 
microglia have been investigated.  
3. we have also explored whether the inhibition of MCP-1 by GCs leads to a 
significant reduction in the chemotactic activity of activated microglia using 
chemotaxis assay.  
 
1.6.2. To study the effects of all-trans-retinoic acid (RA) on microglial activation 
and proliferation  
RA is an active metabolite of vitamin A. It acts through a family of nuclear 
transcription factors known as retinoid receptors (Marill et al. 2003). While the 
principal effects of RA on target cells are inhibition of proliferation and induction 
of differentiation (Maden 2002), RA has also been shown to exhibit 
immunomodulatory and anti-inflammatory activities in various cell types 
(Mathew and Sharma 2000). Further, it has also been demonstrated that RA is 
synthesized in the adult vertebrate brain (Dev et al. 1993; Zetterstrom et al. 1999). 
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In view of these results, it is hypothesized that RA modulates inflammatory 
response and proliferation index of microglia which are the characteristic features 
of activated microglia that respond to injury or neurological disease processes. To 
address this, 
1. effects of RA on inflammatory response of activated microglia have been 
investigated. 
2. the mechanisms by which RA inhibits GM-CSF induced microglia 
proliferation have been studied.  
This research mainly focuses on the mechanisms of inhibitory effects of GCs 
and RA on activated microglia in primary culture. The findings would reveal GCs 
and RA as novel mediators of biological effects and may help to develop better 
therapeutic strategies for the treatment of CNS diseases.
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2.1. Animals and microglia primary culture 
2.1.1. Animals 
Wistar strain rats (postnatal 1-3-day) were used in this study. In the handling 
and care of animals, the International Guiding Principles for Animal Research, as 
adopted by the Institutional Animal Care and Use Committee (IACUC), National 
University of Singapore, were followed. All rats were supplied by the Laboratory 
Animal Center, National University of Singapore, and were kept in the 
Department of Anatomy animal house before the experiments. Rat pups (n = 850) 
were used for primary microglia cultures for Dex related experiments, and rat 
pups (n = 350) were used for primary microglia cultures for RA related 
experiments.  
Table 1. Rat pups used in various experiments 




Immunocytochemistry 48 12 
Real time RT-PCR 36 No 
ELISA 40 27 
Western Blot 300 54 
MTS assay 12 16 
Chemotaxis assay 24 No 
For repeated experiments, another 593 rat pups were used.    
2.1.2. Materials 
Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, USA, Cat. No. 
11966025) 
Insulin (Sigma-Aldrich, USA, Cat. No. I0516) 
Non-essential amino acid (Invitrogen, USA, Cat. No. 11140050)  
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Antibiotic antimycotic solution (100×)(Sigma-Aldrich, USA, Cat.No. 
A5955) 
Trypsin and EDTA (10×)(Invitrogen, USA, Cat. No. 15400-054) 
Deoxyribonuclease Ⅰ (Sigma-Aldrich, USA, Cat.No. D4527) 
Fetal bovine serum (FBS, Invitrogen, USA, Cat. No. 10099)   
70µm nylon mesh (BD Biosciences, USA, Cat. No. 352350) 
75cm2  tissue culture flasks (NUNC, Denmark) 
Lycopersicon esculentum (tomato) lectin (Sigma-Aldrich, USA, Cat. No. 
L0401 ) 
 Propidium iodide (PI) (Sigma-Aldrich, USA, Cat. No. 70335) 
 
2.1.3. Procedure   
2.1.3.1. Removal of brain tissue 
     The rat pups were deeply anesthetized with pentabarbitone (50mg/kg body 
wt) and were decapitated. The heads were wiped with 70% ethanol and washed 
with cold PBS. The skin was incised along the midline in a caudal to rostral 
direction to expose the skull. The skull was penetrated with a tip of a pair of 
scissors medially just caudal to the cerebral hemispheres. This point was easy to 
penetrate as it lies at the juncture of two major sutures of the skull bone. The skull 
was cut-opened rostrally to the nose and then mediolaterally. Further from the 
original point of incision, the skull was cut mediolaterally and then in a rostral 
direction reaching the first set of cuts. In this way, two roughly rectangular flaps 
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of skull were removed. Underlying brain tissue was moistened with cold PBS. A 
pair of curved forceps was run around and under the hemispheres to scoop them 
out of the cortex. The brain tissue was placed onto a 100-mm-diameter dish with 
cold PBS and was rinsed three times. The cortices were collected into a 50-ml 
tube in PBS on ice and were rinsed three times with PBS. The unwanted brain 
region, such as olfactory bulb, basal ganglia, hippocampus, and thalamus, were 
removed firstly. The meninges and superficial vessels were removed subsequently. 
The remaining desired tissue was transferred to a new 60-mm-diameter dish, 
containing cold PBS. The tissue was finely dissected further to remove the 
remaining meninges and vasculature from the dish. Finally, the tissue was 
transffered to a new 60-mm-diameter dish containing 9ml cold DMEM medium. 
 
2.1.3.2. Mechanical dissociation of brain tissue 
      A long pair of serrated forceps or hemostats was used to chop the tissue in 
the dish with gentle up-and-down motion. The tissue pieces were collected and 
mechanically dissociated by pipetting in and out with a 10ml plastic pipette in a 
50-ml sterile concial tube on ice. 
 
2.1.3.3. Enzymatic digestion 
      1ml of Trypsin-EDTA solution (0.5% Trypsine, 0.2% EDTA) and 100μl of 
DNase solution (50μg/ml DNase) were added into the tube, and mixed before the 
solution was transferred to a 75cm2 tissue culture flask The flask was placed in an 
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orbital shaker at 37℃ and shaken at 200rpm/min for 15 min. Cells were passed 
through a 70μm cell strainer to remove remaining clumps of tissue and then 
transferred to a 50ml centrifuge tube again.  
      Finally the cell suspension was centrifuged at 1000rpm for 5 min, then 
seeded in culture dish consisting of DMEM supplemented with 10% fetal bovine 
serum at a density of 1.2×106 cells/ml and cultured at 37℃ in humidified 5% 
CO2/95% air. Medium was changed every 3-4 days and confluency was achieved 
after 10-12 days in vitro.  
 
2.1.3.4. Microglia purification 
      Microglial cultures were prepared by a mild trypsinization method as 
described by Saura et al. (Saura et al. 2003). The mixed glial cultures were 
purified after 10 to 12 days. Briefly, the cultures were washed with PBS twice and 
incubated with a trypsin solution (1ml of 0.25% trypsin and 20μl of 0.5M EDTA 
diluted in 40ml of DMEM) for about 10min. This resulted in the detachment of an 
upper layer of cells which were removed subsequently. The microglial cells 
remained attached to the bottom of the flask and were cultured in DMEM 
supplemented with 10% fetal bovine serum.  
    For immunocytochemistry, cells were plated at 2.5×105 per well on a 24 
multi-well culture dish and incubated at 37°C in a humidified atmosphere of 95% 
air and 5% CO2 for 24h. For immunoblotting and RNA isolation, cells were plated 
at 1×106 cells per 75cm2 flask. For enzyme-linked immunosorbent assay (ELISA), 
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cells were plated at 1×104 cells per well in 96-well plates. The following day, the 
cells were subjected to different treatments.   
      The purity of microglia was assessed immunohistochemically using 
Lycopersicon esculentum (tomato) lectin (1:100), a marker for microglia, and 
Propidium iodide (PI) (20μg/ml) a nuclear marker of all cells attached to the 
coverslips. The purity of microglial cultures was found to be around 96%.  
 
2.2. Treatment of microglia culture 
2.2.1. Materials 
   Lipopolysacharide (LPS) (Sigma-Aldrich, USA, Cat. No. L2762) 
   Dexamethasone (Dex) (Sigma-Adrich, USA, Cat. No. D2915) 
   SP600125, JNK inhibitor (Scientific, Inc. USA, Cat. No. S-2022)  
 SB203580, p38 inhibitor (MERCK, Germany, Cat. No. 559400) 
Triptolide (Calbiochem, Germany, Cat. No. 645900) 
All-trans-retinoic acid (Sigma-Adrich, USA, Cat. No. R2625) 
Granulocyte macrophage-colony stimulating factor (GM-CSF, BD 
Biosciences Pharmingen, USA, Cat No: 555111) 
Fetal bovine serum (Invitrogen, USA, Cat. No. 10099)  
Dimethyl sulfoxide (DMSO, Calbiochem, Germany, Cat. No. 317275) 
Ethanol (BDH Prolabo, Germany, Cat No: 15338-6F) 
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2.2.2. Procedure 
    In order to study the effects of LPS and Dex on activation of microglial cells, 
the cells were washed with PBS and incubated either with LPS (1μg/ml) or Dex or 
LPS plus Dex (10-6 M) in DMEM without serum.  Effects of Dex on MAPK 
pathway were studied by adding Dex (10-6 M) 2 hours prior to LPS in microglia 
cultures. Further, microglia cultures were treated with either SP600125 (1μM) or 
SB203580 (1μM), inhibitors of JNK and p38 respectively, 30 min before LPS 
treatment to examine the effects of MAPK inhibitors on LPS-induced microglia 
activation. To investigate the role of MKP-1 on Dex-induced inhibition of 
microglial activation, microglial cells were pretreated with or without triptolide 
(0.5μM), 30min before the addition of Dex plus LPS. In all the experiments, 
control cells were treated with DMSO/ ethanol as the vehicle at final 
concentrations used in experimental cultures.  
    In order to study the effects of RA on GM-CSF-treated microglia, cells were 
grown in the DMEM containing 1% FBS for 12h, followed by incubation with 
serum-free medium for 24h, a standard means of synchronizing cells in the G0 
phase of the cell cycle. At this time (designed time 0), the medium was replaced 
with DMEM containing 10% FBS and GM-CSF (10ng/ml) with or without RA 
(10μm). The vehicle, DMSO did not exceed 0.1%. Cells were then incubated at 
37℃ in a humidified atmosphere of air/5% CO2 for the times indicated.  
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2.3. Immunofluorescence labeling 
2.3.1. Principle 
    Immunohistochemistry (IHC), or immunocytochemistry, is a method for 
localizing specific antigens in tissues or cells based on antigen-antibody 
recognition. The basic principle of IHC is a sharp localization of target 
components in the cell and tissue, based on a satisfactory signal-to-noise ratio. A 
series of technical developments in IHC have created sensitive detection systems 
and the most commonly used is the enzyme-labled system (for light microscope); 
the fluorescent dye-labled system (for fluorescence microscope); and the 
electron-dense particles-labled system (for electron microscope). To achieve 
greater sensitivity is always the critical issue for the IHC and a large number of 
detection techniques have been developed, including peroxidase antiperoxidase 
(PAP), avidin-biotin conjugate (ABC) and biotin-streptavidin (B-SA) methods.  
    The routine procedure for IHC includes fixation, blocking, the incubation 
with first antibody and detection of first antibody. Fixation is required for the IHC 
to stabilize the tissue or cells and protect them from the rigors of subsequent 
processing and staining techniques. Blocking of nonspecific background staining 
enhances the specificity of the primary antibody. Antibody molecules are labeled 
or flagged to permit their visualization. The detection system can be divided into 
direct conjugate-labeled antibody method and indirect conjugate-labeled antibody 
method. In the direct detection method, an antibody is labeled and then is directly 
applied to the tissue section or cells. In the indirect conjugate-labeled antibody 
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method, the primary antibody that has specificity against the antigen in question is 
added to the sample, followed by addition of the labeled secondary antibody, 
which has specificity against an antigenic epitope present on the primary antibody. 
Thus, the secondary antibody serves to label the primary antibody, which, in turn, 
is bound to the antigen in tissue (Petrusz et al. 1980;Wessel and McClay 1986). 
 
2.3.2. Materials 
MCP-1 (Santa Cruz, CA, USA, Cat. No sc-1785) 
Rabbit phospho-c-Jun (ser73, Cell Signaling Technology, USA, Cat. No.               
9164) 
Fluorochrome-conjugated goat-anti-rabbit secondary antibody (Chemicon, 
USA, AP307F) 
Fluorochrome-conjugated rabbit-anti-goat secondary antibody (Chemicon, 
USA, AP106F) 
4’, 6- diamidino-2-phenylindole dihydrochloride (DAPI) (Molecular 
Probes, USA, Cat. No. D1306) 
Propidium iodide (PI) (Sigma-Aldrich, USA, Cat. No. 70335) 
Fluorescent Mounting Medium (DakoCytomation, Denmark, Cat. No. 
S302380) 
Phosphate Buffered Saline (PBS) (10X) liquid (Invitrogen, USA, Cat. No. 
14200166) 
0.1M phosphate-buffered saline (PBS) 
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0.1M PBS containing 0.1% Triton-X 100 (PBS-TX) 
4% paraformaldehyde (PF): 
   Paraformaldehyde (Sigma)  4g 
0.1M phosphate buffer (pH 7.4) 100ml 
 
2.3.3. Procedure  
    Microglia attached to the coverslips were allowed to grow for 1 day before 
they are incubated with 1μg/ml of LPS in presence or absence of Dex (10-6 M) for 
either 30 min (for c-Jun and phospho-c-Jun detection) or 6h (For MCP-1). After 
the incubation, the cells were fixed in 4% PF for 20min, blocked in 1% bovine 
serum albumin (BSA) for 30min, and incubated overnight with specific primary 
antibodies that were raised in goat and directed against rat MCP-1 (1:100), or 
rabbit phospho-c-Jun (1:100). Subsequently cells were incubated with appropriate 
conjugated secondary antibodies (1:200). Finally, the cells were counterstained 
with nuclear markers either PI (5µg/ml) or DAPI (1µg/ml) and examined under a 
confocal microscope (Olympus Fluoview1000, Japan). For PI, λexcitation = 543 nm, 
λemission = 560 nm; for DAPI, λexcitation =359nm,  λemission = 461;  For FITC, 
λexcitation =488 nm,  λemission = 510nm; For Cy3, λexcitation = 568 nm, λemission 
=630nm                                                  
Quantitative analysis of the number of phospho-c-Jun nuclear positive 
microglial cells was carried out by performing cell count in 8 randomly chosen 
microscopic fields containing about 40 cells in the control cultures and cultures 
treated with LPS in the presence or absence of Dex. The cells with blue nuclei 
were counted as phospho-c-Jun negative; the cells with pink nuclei were counted 
as phospho-c-Jun positive. Each experiment was done in triplicate. 
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2.4. RNA Isolation and Real time reverse transcription-polymerase chain 
reaction (RT-PCR) 
2.4.1. Principle  
The RNeasy technology (Qiagen, Germany) used in this study for RNA 
isolation combines the selective binding properties of a silica-gel-based membrane 
with the speed of microspin technology. A specialized high-salt buffer system 
allows RNA longer than 200 bases to bind to the RNeasy silica-gel membrane. 
Cell or tissue samples are first lysed in the presence of a highly denaturing 
guanidinium isothiocyanate (GITC)-containing buffer, which immediately 
inactivates RNases to ensure isolation of intact RNA. Ethanol is added to provide 
appropriate binding conditions, and the sample is then applied to an RNeasy mini 
column where the total RNA binds to the membrane and contaminants are 
efficiently washed away. High-quality RNA is then eluted in RNase-free water. 
With this RNeasy procedure, all RNA molecules longer than 200 nucleotides are 
isolated while most RNAs shorter than 200 nucleotides such as 5.8S rRNA, 5S 
rRNA, and tRNAs are selectively excluded. 
Polymerase chain reaction (PCR) is a technique used to amplify the number 
of copies of a specific region of DNA in order to produce sufficient amount of 
DNA to be adequately tested. There are three basic steps in a PCR, including 
denaturation, annealing, and DNA synthesis, which are repeated for 30 to 40 
cycles. During these steps, the double-stranded sample DNA melts open to 
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become a single-stranded DNA which is then hybridized with a set of 5’ and 3’ 
end primers, short fragments of DNA that is base-paired to a specific region of 
single-stranded sample DNA. The 3’ end of the primer serves as the starting point 
for the new DNA synthesis in the presence of DNA polymerase and nucleotides. 
Since the reaction mixture contains primers complementary to both strands of 
sample DNA, the products of the DNA synthesis can themselves be copied 
(Mullis and Faloona 1987). 
Reverse transcription combined with polymerase chain reaction (RT-PCR) 
has proven to be a powerful method to quantify the levels of mRNA expression 
(Murphy et al. 1990). The real time, fluorescence-based RT-PCR is a recent 
advance in quantitative RT-PCR technology which enables rapid and reproducible 
high-throughput RT-PCR quantification, with extremely high sensitivity. Hence, 
the real-time RT-PCR has become the method of choice for the quantification of 
gene expression (Bustin 2000;Ginzinger 2002). Real time RT-PCR incorporates a 
specific technology to detect the PCR product following each cycle of the reaction. 
This technology involves a DNA-binding fluorescent dye, such as SYBR green I, 
which binds in the minor groove of double-stranded DNA (Morrison et al. 1998). 
When the DNA is denatured, the unbound dye emits little fluorescence in the 
reaction system. During extension, increasing amount of dye binds to the newly 
formed double-stranded DNA, resulting in an increase in the fluorescence signal. 
Thus, the fluorescence measurement performed at the end of the extension step of 
every PCR cycle reflects the increasing amount of amplified DNA. After a few 
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cycles, the fluorescent signal is first recorded as statistically significant above 
background signal. This point is described as threshold cycle (Ct), which occurs 
during the exponential phase of amplification (Gibson et al. 1996). In addition, the 
specificity of the amplification and PCR product verification can be achieved by a 
melting curve of the PCR product (Ririe et al. 1997).  
 Real time RT-PCR data analysis can be classified as absolute quantification or 
relative quantification. The absolute quantification involves the construction of a 
standard curve based on known copy numbers to determine the input copy number 
of the transcript of interest by relating the PCR signal to the standard curve, 
whereas the relative quantification involves determining the change in gene 
expression level relative to another set of experimental samples such as untreated 
controls or samples at time zero in a time-course study (Livak and Schmittgen 
2001). For most research applications, the relative quantification approach is more 
practical as it compares experimental samples against controls directly. 
Furthermore, a normalization of the target gene with an endogenous reference 
gene is required for the relative quantification. Usually, non-regulated genes or 
housekeeping genes like glyceraldehydes-3-phosphate dehydrogenase (GAPDH), 
albumin, actin, tubulin, cyclophilin, 18S rRNA or 28S rRNA are applicable as the 
reference genes (Marten et al. 1994;Thellin et al. 1999).  
Using the 2-ΔΔCt method (Livak and Schmittgen 2001), the data are 
presented as the fold change of target gene expression normalized to an 
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endogenous reference gene, relative to a calibrator. For the treated samples, 
evaluation of 2-ΔΔCt indicates the fold change of gene expression relative to the 
untreated control. For this method to be valid, the amplification efficiencies of the 
target and reference must be approximately equal.  
2.4.2. Materials 
RNeasy mini kit (Qiagen, Germany, Cat. No. 74106) 
Molony murine leukemia virus reverse transcriptase (M-MLV) (Promega, 
USA, Cat. No. M1701) 
Oligo(dT) primer (Promega, USA , Cat. No. C1101) 
dNTP mix (Promega, USA , Cat. No. U1240) 
RNase inhibitor (Promega, USA , Cat. No. N2111,) 
LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche Applied 
Sciences, Germany , Cat. No. 03515885001,) 
TAE buffer (Invitrogen, USA, Cat. No. 15558034) 
100bp DNA step ladder (Promega, USA, Cat. No. G6951) 
LightCycler instrument (Roche Molecular Biochemicals, ) 
GeneGenius (Syngene, UK) 
Spectrophotometer (Eppendorf, Germany) 
 
2.4.3 Procedure 
2.4.3.1 Extraction of total RNA 
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     Total RNA was extracted from the cells using RNeasy Mini Kit according to 
the manufacturer’s instructions. Approximately, 1×106 cells were used to extract 
the total RNA. Cells were lysed in 650μl of RLT buffer (containing a highly 
denatured guanidine isothiocyanate which inactivates RNase) and then scrapped 
from the flask with the scraper. The lysate was homogenized, then centrifuged for 
30s at 14000g in a microfuge and the supernatant was mixed with 650μl of 70% 
ethanol to clear lysate. The sample was applied to an RNeasy mini spin column 
(silica-gel membrane, maximum binding capacity is 100μg of RNA longer than 
200 bases) and spun for 30sec at 14000g and then flow-through was discarded. 
The RNA bound to the membrane was washed with buffer RW1 and RPE 
sequentially. High-quality RNA was then eluted in 20μl of RNase free water. The 
concentration and purity of the extracted RNA was evaluated 
spectrophotometrically at 260 and 280nm (Biophotometer, Eppendorf, Germany) 
 
2.4.3.2 cDNA Synthesis 
      The cDNA synthesis was carried out in a total volume of 25μl containing 
the RNA template, Oligo(dT) Primer, M-MLV reverse transcriptase, transcription 
buffer, dNTP, RNase inhibitor and RNase-free water. 
       2μg of RNA was added with 1μl Oligo(dT)15 primer into a 
microcentrifuge tube and then heated to 70° for 5min to melt secondary structure 
within the temple. The tube was immediately transferred to ice. The following 
components were added to the annealed primer/template in the order shown. 
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              M-MLV 5 × Reaction Buffer        5μl 
              10 × dNTP Mix                  1.25μl 
              RNase inhibitor                  0.675μl    
              M-MLV Reverse transcriptase       1μl  
              RNase free water to final volume     25μl 
                 
        The reaction mix was mixed gently and incubated for 1h at 42°C. 
Finally the reaction was terminated by heating at 95°C for 5min. The cDNA 
synthesized was kept at 4℃. 
2.4.3.3 Real time RT-PCR  
     Using the LightCycler instrument, the PCR was performed in a total volume 
of 10μl, containing 2μl genomic DNA, 10pmol of each primer, 1μl SYBR Green Ⅰ, 
4mM MgCl2 and water to the final volume. The sequences of the forward and 
reverse primers and the PCR conditions for each gene are given in Table 1.    
Total RNA was extracted from these cultures using RNeasy mini kit 
according to the manufacturer's instructions and quantified spectrophotometrically. 
The reaction mixture containing 2µg of RNA, 2.5µM of oligo (dT) primer, and 
200U of M-MLV in a total volume of 25µl was incubated for 1h at 42°C for 
reverse transcription, and the reaction stopped by heating for 10min at 70°C. 
Aliquot (0.5µl) of the each reverse transcription product was added to the reaction 
mixture (20µl) containing LightCycler-FastStart DNA Master SYBR Green I, 
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0.5µM of each primer corresponding to the rat MCP-1, CCR2, MKP-1 and β actin 
(Table 2.), and 4mM MgCl2 to amplify each of the genes in a LightCycler. The 
primer sequences are listed in Table 1. After pre-incubation at 95°C for 10min, the 
polymerase chain reaction (PCR) was performed as follows: 35 cycles of 
denaturation at 95°C for 15s, annealing at 60°C (for MCP-1 and CCR2) or 62°C 
(for MKP-1 and actin) for 5s, and elongation at 72°C for PCR product size per 25s. 
The expression level of each gene was quantified, expressed as Ct, the cycle 
number at which the LightCycler system detected the upstroke of the exponential 
phase of PCR product accumulation, and normalized by the level of expression of 
β-actin in each individual sample. The mRNA expression levels of various genes 
studied in the experimental groups and control groups were compared using the 
2-[ Ct] method(Livak and Schmittgen 2001). 
 
           Table 2. Primers for real timeRT-PCR 




size   
(bp) 
MCP-1 Forward: tctcttcctccaccactatgca   
Reverse: ggctgagacagcacgtggat 
103 
CCR2 Forward: cgcagagttgacaagttgtg  
Reverse: gccatggatgaactgaggta 
233 
MKP-1 Forward: acttccctgtctccatccct     
Reverse: acgtgaaactccacacctcc 
302 
β-actin Forword: tcacccacactgtgcccatctacg  
Reverse: ggatgccacaggattccataccca  
327 
 
2.4.3.4 Detection of PCR product 
       PCR products were run on agarose gel using electrophoresis. 2% agarose 
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gel was prepared by heating agarose in the TAE buffer. 5% of Ethidum bromide 
was added into the gel and the gel was cooled, poured onto a gel tray and allowed 
to solidify. 10μl of each real time PCR product was loaded in each lane of the gel 
and electrophoresed at 110V for 45min in TAE buffer with 10μl of 100bp DNA 
ladder. The PCR products in gel were visualized with an ultraviolet 
trans-illuminator and photographed. The 100bp DNA ladder was used to 
determine the size of the amplified DNA from 100 to 1000bp. 
 
2.5. Enzyme-linked immunosorbent assays (ELISA)  
2.5.1. Principle 
   Enzyme-linked immunosorbent assays (ELISA) are designed for detecting and 
quantitating substances such proteins and hormones. In an ELISA, an antigen is 
immobilized to a solid surface in 96-well polystyrene plates. The antigen is then 
complexed with an antibody that is linked to an enzyme. Detection is 
accomplished by incubating this enzyme-complex with a substrate which 
produces a detectable product. 
 
2.5.2. Materials 
MCP-1 ELISA kit (Pierce, USA, Cat. No. ERMCP1) 
TNF-α ELISA kit (BD Biosciences,USA, Cat. No. 550734) 
ELISA plate reader (Molecular Devices, USA) 
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2.5.3. Analysis of MCP-1 by ELISA 
    Microglia cultures were treated with LPS, LPS plus Dex, LPS plus SP600125, 
or LPS plus SB203580 for 6h, and the culture medium from each experiment was 
collected. The concentration of MCP-1 released by microglial cells into the 
culture medium was measured using the rat MCP-1 ELISA kit, according to the 
manufacturer’s protocol. Briefly, samples including standards of known MCP-1 
content were incubated in 96-well plates coated with MCP-1 antiserum for 2h. 
The samples were treated in subsequent steps with Enzyme Working Reagent for 
30 min and TMB One-Step substrate reagent for 30min in the dark and the 
reaction plates were read within 30min in an ELISA plate reader at 450 nm. 
 
2.5.4. Analysis of TNF- α by ELISA 
The culture medium from the microglia culture (2.5 ×105 cells/well in a 
24-well plate) was collected 6h after addition of LPS or RA or LPS plus RA in the 
culture and the concentration of TNF-α protein was measured using a solid-phase 
sandwich ELISA kit for rat TNF-α. Briefly, samples including standards of known 
TNF-  content were incubated in 96-well plates coated with TNF-α antiserum for 
2h. Then samples were treated in subsequent steps with Enzyme Working Reagent 
(30min) and TMB One-Step substrate reagent (30min in the dark) and the reaction 
plates were read within 30min in an ELISA plate reader at 450nm. 
 
2.6. Nitrite Assay 
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2.6.1 Principle 
Nitric Oxide is rapidly oxidized to nitrite in culture medium and 
determination of nitrite concentration is used as a measure of NO production. This 
assay, which was first described by Griess in 1879, is based on a chemical 
reaction that uses sulfanilamide and N-1-naphthylethylenediamine 
dihydrochloride (NED) under acidic (phosphoric acid) conditions. 
 
 2.6.2. Material 
Griess reagent system (US Biological, USA; Cat. No. 2577-01)  
 
2.6.3. Procedure 
Culture medium from primary microglia cultures (2.5 × 105 cells/well in a 
24-multi-well) was collected 6 h after addition of LPS or RA or LPS+RA in the 
culture. The quantity of nitric oxide in the culture medium was assessed using a 
colorimetric biogene kit with a Griess reagent system. Equal volumes of culture 
medium and the Griess reagent (0.1% N-(1-naphthyl)ethylenediamine 
dihydrochloride, 1% sulfanilamide, and 2.5% H3PO4) were mixed and incubated 
for 10min at room temperature. The absorbance at 540 nm was determined with 
an E MAX precise microplate reader (Molecular Devices, USA).  
 
2.7. Western Blot Assay 
2.7.1. Principle  
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Western blotting has become one of the most common protein analysis 
techniques used in biomedical research. Western blotting provides a direct method 
for identifying, monitoring, and determining the relative amount of specific 
proteins in different samples. In general, a complex protein mixture (such as cell 
lysate or extract, or purified protein preparation) is fractionated on a gel by 
electrophoresis. After separation, proteins are transferred to a membrane, which 
can be nitrocellulose, polyvinylidene fluoride (PVDF) or nylon. Nitrocellulose 
and PVDF membranes are most commonly used for protein analysis. Primary 
antibodies are used to detect specific protein antigens on the membrane. Detection 
of antibody-antigen immune complexes on a membrane was accomplished using 
secondary antibodies covalently conjugated to horseradish peroxidase (HRP) 
enzyme. The chemiluminescence of HRP substrate is developed on standard X-ray 
film.  
2.7.2. Materials 
Protease inhibitor cocktail kit (Pierce, USA, Cat. No. 78410) 
Mammalian protein extraction reagent (Pierce, USA, Cat. No. 78503) 
Protein assay kit (Bio-Rad, USA, Cat. No. 5000002) 
10% resolving gel: 
H2O      7.9ml 
  30% acrylamide mix   6.7ml 
1.5 M Tris (pH 8.8)   5.0ml 
  10% SDS     0.2ml 
  10% ammonium persulfate 0.2ml 
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  TEMED     0.008ml 
5% stacking gel: 
H2O      5.5ml 
  30% acrylamide mix   1.3ml 
1.0 M Tris (pH 6.8)   1.0ml 
  10% SDS     0.08ml 
  10% ammonium persulfate 0.08ml 
  TEMED     0.008ml 
1x SDS gel-loading buffer: 
50mM Tris.Cl (pH 6.8) 
  100mM dithiothreitol 
  2% SDS 
  0.1% bromophenol blue 
  10% glycerol 
Tris-glycine electrophoresis buffer: 
25mM Tris 
  250mM glycine 
  0.1% SDS 
Transfer buffer: 
25mM Tris 
  250mM glycine 
  20% Methanol 
1X TBS: 
  Tris base   2.42 g 
  NaCl    0.8 g 
  H2O up to 1 liter; adjusted to pH 7.6 with 2N HCl 
1X TBST: 
  1X TBS 1 liter 
  0.1% Tween 20 
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Rabbit anti- phospho-JNK, JNK (Cell Signaling Technology, USA, Cat.      
No. 9250)  
Rabbit anti-phospho-p38, p38 (Cell Signaling Technology, USA, Cat. No. 
9210) 
Rabbit anti-phospho-ERK1/2, ERK1/2 (Cell Signaling Technology, USA, 
Cat. No. 9100) 
MKP-1 (Santa Cruz, CA, USA, Cat. No. sc-1102) 
rabbit anti-rat TNF-α antibody (Chemicon, USA, Cat. No. AB1837P)  
rabbit anti-rat iNOS antibody (BD Transduction Laboratories; USA, Cat. 
No; 610332) 
rabbit anti-Cyclin D1 (Santa Cruz Biotechnology, Inc, USA , Cat. No. 
sc-717) 
Rabbit anti-P27 antibody (Cell Signaling Technology, USA; Cat. No. 
2552) 
Rabbit anti-α-tubulin antibody (Cell Signaling Technology, USA; Cat. No. 
2144) 
Rabbit anti-E2F-1 antibody (Santa Cruz Biotechnology, Inc, USA , Cat. 
No. sc-193) 
Rabbit anti-phosphor-Rb (Ser 807/811) antibody(Cell Signaling 
Technology, USA; Cat. No. 9308) 
Mouse anti-Rb antibody (BD Transduction Laboratories, USA, Cat. No. 
300508) 
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Goat anti-rabbit IgG conjugated with horseradish peroxidase (Cell 
Signaling Technology, USA, Cat. No. 7074) 
Mouse anti- β-actin monoclonal antibody (Sigma-Aldrich, USA, Cat. No. 
A1978) 
Goat anti-mouse IgG conjugated with horseradish peroxidase (Pierce, 
USA, Cat. No. 31430,) 
Stripping buffer (Pierce, USA, Cat. No. 0021059) 
2.7.3. Procedure 
Protein extracts from microglial cultures subjected to various treatments 
for different periods were prepared using the protein extraction kit and protease 
inhibitor cocktail kit, and were quantified using a protein assay kit. Briefly, the 
cultures were washed with cold PBS twice and resuspended in 600μl of protein 
extraction buffer. Cells were then scraped from the culture flask. The supernatant 
was collected by centrifugation at 14,000 g at 4ºC for 15 min and stored at -20ºC 
for further use.   
The concentration of protein extracts was determined using a protein assay 
kit. Four different concentrations (0.06, 0.12, 0.24, and 0.48mg/ml) of BSA were 
prepared as protein standards. 10µl of each standard or sample and 200µl of dye 
reagent were added together to each well of a 96-well plate, and mixed thoroughly. 
The mixtures were incubated at room temperature for 10 min, and the absorbance 
at 595nm was measured using a microplate reader (GENios, Tecan, Switzerland). 
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The concentration of protein extract of the samples was determined according to 
the standard curve of BSA. 
Aliquots of protein extracts (20 µg each) were heated to 100ºC for 3 min in 
1x SDS gel-loading buffer to denature the proteins before the proteins were 
separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Next, the proteins were transferred from the gel to the 0.2µm PVDF 
membranes using a semi-dry electrophoretic transfer cell (Bio-Rad, USA). 
Membranes were washed with TBST buffer and then blocked with 5% non-fat 
milk in TBST for 1h at room temperature. Subsequently, the membranes were 
incubated with appropriate primary antibodies overnight at 4ºC in a shaker. The 
primary antibodies used are as follows: rabbit anti- phospho-JNK, JNK, 
phospho-p38, p38, phospho-ERK1/2, ERK1/2, MKP-1 and mouse anti-actin. The 
next day, blots were incubated with secondary IgG antibody conjugated with 
horseradish peroxidase for 1h at room temperature. Equal amount of protein 
loading was confirmed by reprobing with total kinases or actin antibodies. 
Immunopositive bands were visualized by enhanced chemiluminescence (ECL), 
and quantified by scanning densitometer and Quantity One software, version 4.4.1 
(Bio-Rad, USA). 
2.8. In vitro Chemotaxis Assay 
2.8.1. Materials 
48-well Boyden. microchamber (Neuro Probe, USA, Cat. No. AP48) 
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Fibronectin (BD bioscience, USA, Cat No: 354008) 
 
2.8.2. Procedure  
The in vitro migration of microglia in response to microglia conditioned 
medium was assessed using polyvinylcarbonate-free membranes with 10µm pore 
size in a modified 48-well microchemotaxis Boyden chamber (Neuroprobe, Cabin 
John, MD, USA) as described previously (Cross and Woodroofe 1999a). The 
membrane was coated with 20µg/ml of Fibronectin for 24h. Microglial cells were 
plated at 2.5×105 per well on a 24 multi-well culture dish for 1day and incubated 
with LPS (1µg/ml) in the presence or absence of Dex (10-6 M) for 6h.  The 
optimal dilution of media derived from the control, LPS and LPS+Dex treated 
microglial cultures was determined by measuring the chemotaxic effect of serial 
dilutions (1/2, 1/4 and 1/8). To examine the chemotaxis, 28μl of DMEM or 
conditioned medium collected from the above microglial cultures or rat 
recombinant MCP-1 protein (Chemicon, Cat. No. GF041) dissolved in DMEM 
with different concentrations was added to the lower chambers. In some 
experiments, rabbit anti-MCP-1 antiserum (10μg/ml) or another antiserum raised 
in rabbit (10μg/ml; anti-iNOS) as the control was added together with the 
LPS-treated microglia conditioned medium in the lower chambers in order to test 
the neutralization effects of anti-MCP-1. We also examined the chemotactic effect 
of microglial cells in LPS+Dex treated culture medium supplemented with rat 
recombinant MCP-1 protein (62.5ng/ml). 
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Microglial cells (1X106/ml) in 50μl of serum free migration medium, 
DMEM and 0.5% BSA were incubated in the upper chambers for 5h at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. At the end of experiment, the 
upper surfaces of membranes were scraped free of cells and debris, fixed in 4% 
paraformaldehyde and stained using crystal violet. Cells that had migrated through 
pores and adhered to the lower surfaces of the membranes were counted under the 
light microscope and photographed. 
 
2.9. Cell proliferation assay 
2.9.1. Principle  
 MTS based colorimetric assay kit (Promega, USA) was used in the microlgia 
proliferation assay. MTS is yellow tetrazolium salt, which can be converted by the 
activity of cellular mitochondrial dehydrogenases into orange formazyl products 
that are soluble in aqueous solutions. This conversion occurs only in metabolically 
active cells. The quantity of formazan products as measured at the 490nm 
absorbance is directly proportional to the number of living cells in culture.  
 To determine the number of viable cells in culture, cells are grown in a 
96-well tissue culture plate and incubated with the yellow MTS solution for 4 
hours. At the end of incubation, orange formazan solution is formed which can be 
quantified using a microplate reader (GENios, Tecan, Switzerland). An increase in 
number of living cells results in an increase in the overall activity of 
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mitochondrial dehydrogenases in the sample. This increase directly correlates to 
the amount of orange formazan formed. 
2.9.2. Materials 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Cat. No. 
G3580, Promega, USA) 
2.9.3. Procedure 
     To study the effects of RA on the proliferation of  microglial cells in 
primary cultures, microglial cells were seeded on 96-well plates at a density of 
1x104/ml in 100µl of control, or RA(10µm), GM-CSF (10ng/ml), or GM-CSF 
plus RA per well. After 1 day or 4 days of incubation, 20µl of MTS reagent was 
added into each well containing microglial cultures. To study the effect of JNK 
inhibitor SP600125 or p38 inhibitor SB202380 on microglial cell viability, 
microglial cells were seeded on 96-well plates at a density of 1x104/ml in 100µl of 
control, 1μM SP600125 or 1μM  SB202380 per well. After 6h of incubation, 
20µl of MTS reagent was added into each well containing microglial cultures. The 
cultures were incubated for 4h at 37ºC in a humidified atmosphere of 5% CO2 and 
95% air before the absorbance at 490nm was measured using a microplate reader 
(GENios, Tecan, Switzerland). The absorbance is directly proportional to the 
number of microglia in each well at each time course. The relative increase of the 
number of microglia in each of the four groups was represented by the ratio of the 
absorbance to the control absorbance. The results are expressed as mean ± SD of 
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the ratios. 
2.10. BrdU incorporation assay 
2.10.1. Principle  
Evaluation of cell cycle progression is essential for investigations in many 
fields of biological sciences. Measurement of [3H] thymidine incorporation in 
cells that enter S phase during cell cycle has long been the traditional method for 
the detection of cell proliferation. Quantification of [3H] thymidine incorporation 
is performed by scintillation counting or autoradiography. This technology is slow, 
labor intensive and has several limitations including the handling and disposal of 
radioisotopes and the necessity of expensive equipment.  
A well-established alternative to [3H] thymidine uptake has been 
demonstrated by numerous investigators(Gratzner 1982;Lanier et al. 
1989;Wynford-Thomas and Williams 1986). Bromodeoxyuridine (BrdU), a 
thymidine analog, is incorporated into newly synthesized DNA strands of actively 
proliferating cells. Following partial denaturation of double stranded DNA, BrdU 
can be detected immunohistochemically using the anti-BrdU antibody. The 
proliferation index of the cells is analyzed by quantifying the percentage of BrdU 
positive cells. 
2.10.2. Materials 
5-bromo-2-deoxyuridine (BrdU) (Sigma-Aldrich, USA, Cat. No. B5002) 
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Mouse anti-BrdU monoclonal antibody (Sigma-Aldrich, USA, Cat. No. 
B2531) 
Cy3-conjugated goat anti-mouse IgG (Chemicon, USA, Cat. No. AP124C) 
Lycopersicon esculentum (tomato) lectin (Sigma-Aldrich, USA, Cat. No. 
L0401 ) 
Propidium iodide (PI) (Sigma-Aldrich, USA, Cat. No. 70335) 
Fluorescent Mounting Medium (DakoCytomation, Denmark, Cat. No. 
S302380) 
Phosphate Buffered Saline (PBS) (10X) liquid (Invitrogen, USA, Cat. No. 
14200166) 
0.1M phosphate-buffered saline (PBS) 
0.1M PBS containing 0.1% Triton-X 100 (PBS-TX) 
4% paraformaldehyde (PF) 
     4g paraformaldehyde 
     100 ml 0.1M PBS (PH=7.4) 
2.10.3. Procedure 
Microglial cells were transferred onto poly-L-lysine-coated coverslips in 
24-well plates. Microglial cells were induced by GM-CSF for 1d before they were 
incubated with BrdU (10µmol/l) for 2h. The cells were washed twice with PBS 
and fixed with 4% PF for 20min at 4ºC. Subsequently cells were treated with 2N 
HCl at 37ºC for 30min, washed with PBS twice, blocked with 2% normal goat 
serum for 30min, and incubated with anti-BrdU monoclonal antibody (1:1000) 
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overnight at 4ºC. Further, the cells were washed with PBS, incubated with goat 
anti-mouse secondary antibody conjugated with Cy3 (1:200) for 1h at room 
temperature and counter-stained with lectin (1:100) for counting the total 
microglial cell number. The percentage of BrdU positive cells was determined by 
randomly scoring 5 fields for each experimental and control groups in each 
independent experiment (n=3). The proliferation index is expressed as mean ± SD 
of the percentage of BrdU positive cells.  
 
2.11. Statistical Analysis 
The data of experiments were presented as mean ± SD. The standard 








Where, x = individual observation, and n = number of observations 
Statistical analyses for various experiments performed in this study were 
carried out by Student’s t-test or one-way ANOVA using the Microsoft Excel and 
















3.1. Microglial cells in primary culture 
Primary cultures of microglial cells with approximately 96% purity were 
prepared from brains of postnatal 1-2 days rats. The purity of these cells was 
confirmed by staining them with lectin, a known marker for rat microglia (Figs. 
1A-C). The microglial cells exhibited a dendritic morphology with many highly 
ramified processes (Fig. 1A), and when activated with LPS in the serum-free 
medium, they became amoeboid in shape. The activated microglial cells appeared 
hypertrophic and contained abundant cytoplasmic inclusions (Fig.1B). A majority 
of the LPS-stimulated microglial cells pretreated with Dex showed ramified 
cytoplasmic processes of various degrees as observed in untreated culture (Fig. 
1C). 
 
3.2. Dex suppressed MCP-1 production in activated microglia via inhibition 
of MAP kinase pathway  
3.2.1. Dex inhibited the MCP-1 mRNA expression in activated microglial cells 
MCP-1 mRNA (91bp) was amplified from untreated miroglial cultures by the 
real time RT-PCR (Fig. 2A, B). The effect of Dex on mRNA expression level of 
MCP-1 in LPS-treated microglia was analyzed (Fig. 2C). The mRNA expression 
level of MCP-1 was found to be significantly increased to about 22 fold in 
microglial cells treated with LPS. This increase was inhibited significantly, 





3.2.2. Dex inhibited the MCP-1 expression and release in activated microglial 
cells 
Immunocytochemical analysis reveals that MCP-1 positive cells were hardly 
detectable in the untreated microglial cultures (Fig. 3A). However, LPS markedly 
induced the MCP-1 immunoreactivity in a majority of microglial cells in the 
primary culture (Fig. 3B).  The intensity of MCP-1 immunoreactivity in the 
microglial cells treated with LPS appeared to be reduced by Dex (Fig. 3C). In line 
with these findings, MCP-1 release as revealed by ELISA was increased in 
microglia cultures treated with LPS and the Dex significantly inhibited the 
LPS-induced MCP-1 release from microglia cells (Fig. 4).  
       
3.2.3. Dex suppressed the LPS-induced JNK and p38 MAP kinases activation in 
microglial cells 
  Since GCs have been shown to inhibit a number of MAP kinase family 
members and MAPK signaling transduction pathway, which plays a significant 
role in inducing the expression of inflammatory genes in many immune cell types 
(De et al. 2003), I examined whether Dex inhibits the LPS-induced activation of 
MAP kinases in primary microglial cultures. Western blot analysis showed that the 
LPS treatment induced rapid and time-dependent phosphorylation of JNK (Fig. 
5A, B) and p38 (Fig. 6A, B) in microglial cells. The phosphorylated JNK and p38 
levels increased at 15min, peaked at 30min and 1h and gradually declined to basal 
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levels at 4h. LPS-induced phosphorylation of JNK (Fig. 5A, B) and p38 (Fig. 6A, 
B) was significantly reduced at all time points studied when microglial cells were 
pretreated with Dex 2h prior to LPS treatment. In addition, LPS treatment induced 
phosphorylation of ERK1/2 in microglial cells (Fig. 7A, B). The phosphorylated 
ERK level was increased to peak within 30min of incubation. Unlike JNK and p38, 
however, ERK1/2 level was found to be decreased only modestly at 4h after 
achieving maximal activation following LPS treatment. In addition, Dex treatment 
did not alter the phosphorylation of ERK1/2 significantly in microglial cells 
treated with LPS. 
 
3.2.4 Dex inhibited LPS-induced c-Jun phosphorylation in microglial cells 
As JNK mediates N-terminal phosphorylation of c-Jun (De et al. 2003), 
effects of Dex on the c-Jun phosphorylation in LPS-treated microglia was 
examined. While the immunoreactivity of phospho-c-Jun was undetectable in 
untreated microglial cells, it was markedly induced in a majority of microglial 
cells in cultures treated with LPS (Figs. 8A, B, D). Dex decreased the number of 
phosphorylated c-Jun immunoreactive cells significantly in microglial cultures 
treated with LPS (Fig. 8C, D). 
  
3.2.5 Dex suppressed MCP-1 release by inhibiting the JNK and p38 MAPK 
pathway in activated microglia   
It was hypothesized that Dex suppresses MCP-1 production in activated 
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microglial cells by altering the MAPK pathways, since phospho-c-Jun has been 
shown to induce the expression of MCP-1 in microglia (Waetzig et al. 2005). In 
order to address this, MCP-1 production was measured in LPS-induced microglial 
cells exposed to pharmacological agents, SP600125 and SB203580 which are 
selective inhibitors of JNK and p38 respectively. Incubation of microglial cells 
with SP600125 or SB203580, 30min prior to LPS treatment for 6h decreased the 
LPS-induced MCP-1 release by 24% and 40%, respectively (Fig. 9). Both the 
inhibitors of JNK and p38 mimic the inhibitory effect of Dex on MCP-1 
production, suggesting that Dex suppresses the MCP-1 production by inhibiting 
the JNK and p38 MAPKs. Addition of SP600125 (1μM) or SB203580 (1μM) in 
microglial cultures did not affect the viability of microglia as revealed by the MTS 
assay (Fig. 10). 
 
3.2.6. Dex inhibited MCP-1 production in activated microglia via MKP-1 
dependent JNK and p38 MAPK pathways 
3.2.6.1. Dex induced MKP-1 mRNA and protein expression:  
GCs are known to inhibit the activation of JNK and p38 by up-regulating the 
expression of MKP-1 in several cell types (Lasa et al. 2002). I therefore 
investigated whether MKP-1 was involved in the inhibitory effect of GCs on the 
MAPK pathway in primary culture of microglia. The real time RT-PCR analysis 
showed that MKP-1 mRNA expression level was elevated by 27 fold or 19 fold in 
microglial cells exposed to LPS or Dex respectively, in comparison to that of 
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control (Figs 11A-C). Dex treatment further enhanced MKP-1 gene expression to 
149 fold in the LPS-treated microglia (Fig. 11C). Western blot analysis showed 
that the MKP-1 protein level (42KDa) was very low in untreated microglial cells 
(Figs. 12A, B). LPS stimulated MKP-1 protein expression significantly in 
microglial cells within 15min of treatment. The expression level reached its 
maximum by 1-2h, and then decreased to basal level. Dex treatment further 
enhanced LPS-induced MKP-1 protein expression significantly in microglial cells 
from 30min onwards. However, the MKP-1 protein expression levels induced by 
Dex alone in microglial cells were constant at all time points studied (Fig. 13A, 
B). 
3.2.6.2 Inhibition of MKP-1 expression by triptolide blocked the inhibitory effect 
of Dex on phosphorylation of JNK and p38 
 We next investigated whether inhibition of MKP-1 expression blocked the 
inhibitory effect of Dex on phosphorylation of JNK and p38 in activated 
microglial cells.  Western blot analysis revealed that triptolide inhibited the 
Dex-mediated upregulation of MKP-1 protein expression in activated microglial 
cells (Fig. 14). Furthermore, the inhibitory effects of Dex on the phosphorylation 
of JNK and p38 in activated microglial cells were abrogated by the triptolide. The 
triptolide alone had no effect on MAPKs phosphorylation.  Neither Dex nor 





3.2.6.3 Inhibition of MKP-1 expression suppressed Dex-induced downregulation 
of MCP-1 mRNA expression in activated microglia 
Further, effect of triptolide on MCP-1 mRNA expression in Dex-treated 
activated microglial cells was examined. The quantitative analysis by real time 
RT-PCR showed that triptolide pretreatment increased MCP-1 mRNA expression 
to 2.9 fold in microglial cells treated with LPS plus Dex in comparison to that of 
cells treated only with LPS plus Dex (Fig. 15). These results suggest that Dex 
suppresses the MCP-1 production in activated microglial cells by enhancing the 
expression of MKP-1 and subsequent inhibition of the JNK and p38 
phosphorylation.  
   
3.2.7. Dex inhibited the mRNA and protein expression of CCR2 in activated 
microglia 
The PCR product of CCR2 (233bp) was amplified in microglia cultures on 
Gel (Fig. 16A). The effect of Dex on mRNA expression level of CCR2 in 
LPS-treated microglia has been analyzed by the real time RT-PCR(Fig. 16B, C).  
The quantitative analysis revealed that the LPS increased CCR2 mRNA 
expression level to 11 fold in microglial cultures and the increase was reduced by 
about 32% with the addition of Dex in microglial cultures. CCR2 
immunoreactivity was hardly detectable in the untreated microglial cells (Fig. 
17A). It was, however, markedly increased in most of the cells in the microglial 
cultures challenged with LPS (Fig. 17B). Treatment of Dex significantly 
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suppressed the intensity of the CCR2 immunoreactivity in microglial cells 
exposed to LPS (Fig. 17C).  
                 
3.2.8. Dex inhibited MCP-1-mediated migration of microglia to medium from 
activated microglial cultures 
As it has been shown that Dex inhibits MCP-1 production in activated 
microglial cells in this study, effects of Dex and MCP-1 on the migration of 
microglia was investigated by an in vitro chemotaxis assay. The chemotaxis assay 
confirmed that MCP-1 induced the migration of microglia in a dose-dependent 
manner (Fig. 18). The maximum effect of MCP-1 on migration of microglia was 
at the concentration of 62.5ng/ml. We then investigated chemotactic effects of the 
conditioned-medium derived from the control (untreated) microglial cultures, 
microglia cultures treated with LPS with or without Dex (10-6 M) on the migration 
of microglial cells. The optimal dilution of these media determined by chemotaxis 
assay was found to be 1/4 dilutions (Fig. 19). The strongest chemoattraction was 
observed in LPS medium diluted 1/4. The optimal conditioned-medium from 
LPS-treated microglial cultures was able to attract more microglial cells than the 
medium from control microglial culture or DMEM. LPS-induced microglial 
migration was inhibited significantly by both Dex and 10μg/ml of anti-MCP-1 
antiserum (Fig. 20A, B). When the LPS medium was supplemented with unrelated 
antiserum from the same species of anti-MCP-1 as the control, the migration of 
microglia was not inhibited. Moreover, the inhibition by Dex was partly reversed 
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when recombinant MCP-1 (62.5 ng/ml) was supplemented in the LPS plus Dex 
treated medium, confirming that inhibition of chemotactic activity by Dex is 
mediated via downregulation of MCP-1. 
 
3.3 RA inhibited inflammatory response of activated microglia by 
suppressing TNF-α and iNOS expression 
3.3.1 RA suppressed the expression of TNF-α and iNOS in the microglia 
exposed to LPS 
Immunohistochemically, both TNF-α and iNOS positive cells were hardly 
detectable in the untreated microglial cells (Fig. 21A, D). LPS markedly induced 
the TNF-α and iNOS immunoreactivity in most of the cells in the microglial 
cultures (Fig. 21B, E). These cells appeared to be reactive as they showed an 
increase in size and abundant cytoplasm with cytoplasmic inclusions. Significantly, 
RA (10μM) reduced the intensity of the TNF-α and iNOS positive staining and the 
number of TNF-α and iNOS positive cells in LPS-treated microglial cultures (Fig. 
21C, F). Furthermore, these cells displayed phenotypic features as in the untreated 
cultures.The effect of RA on LPS-induced TNF-α and iNOS protein expression 
has also been analysed by Western blot. LPS has been found to induce both 
TNF-α and iNOS protein expression in the microglia of primary cultures, whereas 
RA suppressed significantly the LPS-induced TNF-α and iNOS protein expression 
in microglia (Fig. 22A, B). The inhibitory effects of RA on TNF-α and iNOS 
protein expression in LPS-stimulated microglia were further confirmed by ELISA 
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for TNF-α and nitrite assay, respectively.  ELISA revealed that RA reduced the 
release of TNF-α from LPS-stimulated microglia by 44%, and nitrite assay 
indicated that RA reduced the production of NO in the microglia exposed to LPS 
by 58% (Fig. 22C).  
 
3.3.2. RA inhibited JNK phosphorylation and induced MKP-1 expression in 
LPS-stimulated microglia 
    As RA suppressed the LPS-induced expression of proinflammatory gene, 
TNF-α and iNOS which are known to be regulated by JNK MAP kinase signaling 
pathway,  we examined whether JNK MAPK signaling pathway was involved in 
RA action on inflammatory response of microglia by Westen blot analysis. LPS 
has been found to induce JNK phosphorylation within 30min in microglial cells 
(Fig. 23). Pretreatment of RA (10μm) for 2h significantly inhibited the 
phosphorylation of JNK in LPS-treated microglial cells. MKP-1 is a 
dual-specificity phosphatase which dephosphorylates and inactivates JNK. To 
determine whether the suppression of JNK MAP kinase by RA in activated 
microglial cells is mediated by MPK-1, the protein expression level of MKP-1 has 
been analysed in microglial cells exposed to RA and LPS. The MKP-1 expression 
was found to be induced in microglial cells exposed to LPS for 30min. In addition, 
pretreatment of these activated microglial cells with RA for 2h further increased 
the induction of MKP-1 expression (Fig. 23). RA-induced upregulation of MKP-1 
was consistent with the inhibitory effect of RA on JNK MAPK, suggesting that 
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the inhibitory effect of RA on the phosphorylation of JNK may be mediated via 
upregulation of MKP-1 expression. 
 
3.4. RA inhibited GM-CSF-induced microglial proliferation by regulating cell 
cycle-associated proteins 
3.4.1 RA inhibited GM-CSF-induced proliferation of microglia 
   The proliferation rate of microglia was detected by BrdU incorporation assay. 
Since the role of GM-CSF in inducing the proliferation of microglia has been well 
established, I explored whether RA has any effect on GM-CSF-induced 
proliferation of microglia. GM-CSF treatment increased the number of BrdU 
positive microglial cells in the primary culture (Fig. 24A, B, D). However, the 
number of BrdU positive microglial cells was significantly decreased in culture 
exposed to RA together with GM-CSF (Fig. 24C, D). The identity of the 
proliferating cells was confirmed to be microglia by labeling the cells with lectin, 
the marker of microglial cells. This result implies that RA inhibits the proliferation 
of microglia. This was further comfirmed by MTS assay (Fig. 25), which showed 
that RA inhibits the proliferation of microglia induced by GM-CSF. In addition, 
RA did not affect the viability of microglial cells in culture. 
 
3.4.2. RA altered expression of cell cycle associated proteins in GM-CSF 
stimulated microglia 
The mechanisms by which RA inhibit the GM-CSF-induced microglial 
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proliferation has been analysed. I initially analyzed cyclin D1, which is the 
regulatory subunit of the cyclin D/CDK4/6 holoenzyme and one of the 
rate-determining factors for cells to progress through the G1/S checkpoint in the  
late G1 phase of cell cycle (Bruce et al. 2007). The protein expression of cyclin 
D1 in microglial cells was increased by GM-CSF (10ng/ml) treatment, and this 
increment was inhibited by RA (10μM) (Fig. 26). This result suggests that RA 
inhibits the proliferation of microglial cells at least in part by reducing the protein 
expression of cyclin D1. 
The activity of cyclinD1 is regulated by a group of cyclin-dependent kinase 
inhibitory proteins, among which p27 has been shown to play a critical role in the 
negative control of the G1/S cell cycle transition (Koguchi et al. 2003). Therefore, 
the expression level of p27 protein was determined by Western blot analysis in 
GM-CSF stimulated microglia culture in the presence or absence of RA (Fig. 26).  
The protein expression of p27 was decreased in microglial cells exposed to 
GM-CSF and the decrease was restored by the addition of RA. Taken together, 
these results imply that RA inhibits the cell cycle progression of microglia by 
inducing the expression of p27, the inhibitor of CDK.  
Since the cyclin D/CDK complex is a major negative regulator of Rb 
protein at the G1 phase of the cell cycle, I analyzed the level of total and 
phosphorylated Rb in GM-CSF or GM-CSF plus RA treated microglial cells. The 
protein level of total Rb was decreased in microglial cells by GM-CSF treatment 
and this decrease was reversed by RA. However, in contrast to total Rb, the 
Results 
 81
phosphorylated RB (phospho-Rb) was significantly increased by GM-CSF and the 
increase was reduced by RA treatment (Fig. 26). These results confirm that RA 
alters the functionality of Rb by increasing the expression of total Rb and by 
reducing the phosphorylation of Rb. 
 It has been shown that E2F-1 which is bound to Rb, induces expression of 
genes involved in cell cycle progression once it is released upon phosphorylation 
of Rb (Bruce et al. 2007). Since the phosphorylation of Rb was inhibited by RA in 
GM-CSF-induced microglial cells, I have analysed the effect of RA on the 
expression of E2F-1 in GM-CSF induced microglia cells. It has been found that 
E2F-1 expression was induced in microglial cells treated with GM-CSF. This 

















4.1 Dex suppresses the migration of activated microglia 
4.1.1 Dex suppresses MCP-1 production and subsequent microglial migration 
    It is well established that activated microglial cells become hypertrophic, 
undergo rapid proliferation and migrate to the inflammatory sites where they 
produce excess amount of neurotoxic and proinflammatory mediators which cause 
deleterious damage to neurons in chronic neuropathological conditions (Vilhardt 
2005). Several drugs have been used to limit the microglia activation by 
suppressing the release of neurotoxic mediators, and the proliferation as well as 
the migration of microglia. It has been widely demonstrated that GCs suppress the 
activation of microglial cells by inhibiting their secretion of proinflammatory 
mediators. The present study has shown that Dex, the synthetic GC, inhibits the 
migration of microglial cells by suppressing the release of MCP-1, a chemokine 
which regulates migration of activated microglial cells to the inflammatory sites in 
the CNS.  
Activation of microglia and associated induction of chemokines have been 
well documented in various acute and chronic neuropathological conditions 
(Ambrosini and Aloisi 2004). Activated microglia release chemokines which 
facilitate the chemotaxis of leukocytes and microglial cells themselves and 
amplify the CNS inflammation (Hanisch 2002; Ambrosini and Aloisi 2004). 
Although microglial activation mainly contributes to neuroprotection, it has been 
widely accepted that inappropriately or persistently activated microglia could 
cause neuronal damage in chronic CNS diseases (Ambrosini and Aloisi 2004). 
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Hence, understanding the mechanisms that inhibit neurotoxic effect of microglial 
cells and that modulate the chemokine network may offer new specific windows 
for treatment of immune-mediated brain diseases. 
Previous studies have shown that Dex inhibits the microglial activation by 
downregulating the neurotoxic and proinflammatory mediators such as NO, 
TNF-α and IL-6 ( Chao et al. 1992; Golde et al. 2003; Lieb et al. 2003;). In the 
present study, Dex  has been found to inhibit the LPS-stimulated mRNA 
expression and protein release of MCP-1 in activated microglial cells, as 
demonstrated in the brain endothelial cells (Harkness et al. 2003). MCP-1 binds 
with its receptor CCR2 to induce a variety of effects including transient 
mobilization of intracellular calcium and subsequent changes in actin 
polymerization which contributes to the microglial migration when activated 
(Cross and Woodroofe 1999). The rapid influx of microglial cells to the injury 
sites in CNS diseases contributes to phagocytosis and controling the 
neuroinflammation. However, overcrowding of these cells around the injury site 
could exacerbate the neuroinflammation (Ambrosini and Aloisi 2004).  The 
decreased expression of MCP-1 by Dex as demonstrated in this study could 
reduce the microglial migration so that augmentation of inflammation is inhibited. 
The chemotaxis assay also further confirmed that Dex or MCP-1 neutralization 
with its antibody inhibits the microglial recruitment towards the conditioned 
medium derived from LPS-treated microglial cultures, indicating that suppressive 
effect of Dex on migration of microglial cells is mediated by the downregulation 
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of MCP-1 expression.  
   The efficacy of GCs is well established in the treatment of bacterial 
meningitis, brain edema, and a number of autoimmune diseases such as multiple 
sclerosis (Gomes et al. 2005; Sloka and Stefanelli 2005). The present study 
demonstrates that GCs could block the development and progression of the 
neurological disorders by inhibiting the MCP-1 expression and subsequent 
microglial recruitment to the injury sites. This is further strengthened by recent 
reports which demonstrated that proteolytic activation of MCP-1 by protease 
tissue plasminogen activator (tPA) enhances the microglial migration and that 
GCs inhibit tPA expression and corresponding enzyme activities ( Eberhardt et al. 
2005; Sheehan et al. 2007), suggesting that the suppressive effect of Dex on 
microglial migration is mediated via inhibition of MCP-1. However, it needs to be 
emphasized that involvement of other chemotactic proteins in migration of 
microglia can not be excluded since there was only a partial inhibition of 
microglial migration after MCP-1 neutralization with its antibody.  
 
4.1.2 Downregulation of MCP-1 expression in activated microglial cells by Dex 
is mediated via MKP-1-dependent inhibition of JNK and p38 MAPK pathways 
I next investigated the molecular mechanisms by which Dex inhibits MCP-1 
production in activated microglial cells. GCs have been consistently shown to 
inhibit the expression of pro-inflammatory genes by antagonizing the MAPK 
pathways, in particular the p38 and JNK pathways. To this end, the inhibition of 
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JNK and p38 MAPK pathways by GCs has been found to be mediated via 
induction of MKP-1 (Chen et al. 2002). However, there is very little information 
about the molecular basis linking GCs to MCP-1. This study provided initial clue 
that MAPK pathway is involved in inhibition of MCP-1 release by GCs in the 
activated microglia. Members of the MAPK families mediate transcriptional and 
posttranscriptional changes in gene expression in response to proinflammatory 
stimuli such as LPS (Hommes et al. 2003).  MAPK activity is regulated 
negatively by MKP-1, the expression of which was found to be induced by GCs in 
myeloid and non-myeloid cells ( Kassel et al. 2001; Chen et al. 2002; Lasa et al. 
2002; Engelbrecht et al. 2003). Several pro-inflammatory stimuli, such as LPS 
also induce MKP-1 expression which, however, activates a negative feedback loop 
down-regulating the production of pro-inflammatory cytokines such as TNF-α and 
IL-1 and IL-6 (Chen et al. 2002; Shepherd et al. 2004; Zhao et al. 2005).  
Recently it has been shown that endocannabinoid anandamide (AEA) which is 
released after brain injury and is believed to attenuate neuronal damage, induces 
MKP-1 expression and subsequent ERK-1/2 MAPK dephosphorylation in 
activated, but not in resting microglial cells which in turn abolishes NO release 
and finally results in neuroprotection (Eljaschewitsch et al. 2006). In the present 
study, Dex induced MKP-1 expression and inhibited phosphorylation of JNK and 
p38 MAPKs in activated microglial cells. The phosphorylation of c-Jun, the JNK 
substrate, was also suppressed in LPS-stimulated microglial cells exposed to Dex.  
It appears that the inhibition of phosphorylation of JNK and p38 MAPKs in 
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activated microglial cells exposed to Dex is due to induced expression of MKP-1 
as it has been shown to be a negative regulator of MAP Kinases in various other 
cell types (Imasato et al. 2002; Sakai et al. 2004; Roger et al. 2005). This effect 
was further confirmed since blocking of MKP-1 induction by triptolide prevented 
the inactivation of JNK and p38 in activated microglial cells by Dex. Moreover, 
recent studies in MKP-1 knockout mice showed that Dex was unable to inhibit the 
LPS-induced JNK and p38 activation in bone marrow-derived macrophages 
(Abraham et al. 2006). It has also been reported that Dex accelerates deactivation 
of p38 and JNK following LPS stimulation in wild-type but not in the 
MKP-1-deficient peritoneal macrophages elicited by thioglycollate (Wang and Liu 
2007). Taken together, these results strongly support the notion that Dex inhibits 
JNK and p38 phosphorylation in microglial cells by inducing MKP-1 expression, 
resulting in downregulation of proinflammatory genes. However, the 
MKP-1-mediated signaling pathway appears to be complex since the 
phosphorylation of ERK1/2 MAPK was unaffected in activated microglia by Dex, 
while GCs could inhibit the phosphorylation of ERK1/2 by inducing rapid 
up-regulation of MKP-1 expression in other cell types such as osteoblast cell lines 
(Engelbrecht et al. 2003). This indicates that GCs action is cell type-dependent. 
Moreover, the upregulation of MKP-1 expression was evident in activated 
microglial cells only after 30min of incubation with LPS plus Dex, although the 
downregulation of JNK and p38 MAP kinases occurred within 15min of 
incubation with LPS plus Dex.  This prompts to speculate the possibility that 
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inhibition of p38 and JNK by Dex also involves phosphatases other than MKP-1, 
particularly in early phase (Cadalbert et al., 2005). 
Activation of MKP-1 has also been shown to inhibit the production of 
pro-inflammatory cytokines such as TNF-α in several cell types (Chen et al. 2002). 
The present study revealed that induced MKP-1 expression in activated microglial 
cells treated with Dex contributed to downregulation of the MCP-1 mRNA 
expression. This effect appeared to be mediated via MAPK pathways since the 
inhibition of MKP-1 expression by triptolide enhanced the phosphorylation of 
JNK and p38 MAPK and the mRNA expression of MCP-1 in activated microglial 
cells treated with Dex. Further, the involvement of JNK and p38 MAPK pathways 
in induction of MCP-1 production in activated microglial cells was confirmed as  
there was an attenuation of MCP-1 protein release when microglial cells were 
treated with inhibitors of JNK and p38 signaling pathways. Moreover, MCP-1 
promoter has been shown to contain functional consensus sequences of c-Jun, a 
primary transcription factor which is phosphorylated by JNK ( De et al. 2003; 
Waetzig et al. 2005). Hence, the inhibition of c-Jun phosphorylation by Dex in 
activated microglia cells suggests that Dex inhibits MCP-1 via MAPK pathways. 
However, it should be noted that the inhibition of MKP-1 protein expression by 
triptolide treatment could not restore the MCP-1 mRNA expression completely in 
microglial cells exposed to LPS plus Dex. This could be due to the fact that the 
triptolide, an active component purified from the medicinal plant Tripterygium 
wilfordii Hook F., is a pleiotropic causing widespread effects including the 
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inhibitory effect on MCP-1 expression via inhibition of Stat3 phosphorylation and 
NF-κB activity (Liu et al. 2006). As mentioned earlier, MKP-1 mediated signaling 
pathway appears to be complex, since its expression is induced by various 
immune suppressive factors including GCs, TGF-β and endocannabinoid 
anandamide. Hence further studies are required to unravel the regulatory 
mechanisms of MKP-1 by GCs in microglial cells in the CNS.  
 
4.2. RA suppresses activation and proliferation of microglia 
4.2.1. RA inhibits the neurotoxic effect of activated microglia by suppressing the 
expression of TNF-α and iNOS  
This study demonstrates that RA inhibits the neurotoxic effect of microglia by 
suppressing the expression levels of proinflammatory cytokine, TNF-α and iNOS 
induced by LPS. Microglial activation and associated induction of 
proinflammatory cytokines and NO have been well documented in various 
neurodegenerative diseases, such as AD and PD. It is believed that the activated 
microglia exert cytotoxic effects in the brain through two different processes, such 
as phagocytosis of cellular debris and the release of a large variety of potentially 
noxious substances (Banati et al. 1993). Both TNF-α and iNOS have been 
implicated as important mediators of the inflammatory response and they 
contribute to most of the neurotoxic activity exerted by the activated microglia 
(Combs et al. 2001). Although the microglial activation is elicited by neuronal 
damage, it has been widely accepted that their cytotoxic effects in turn contribute 
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to the pathogenesis of neurodegeneration (Kalaria 1999). Hence, understanding 
the mechanisms that inhibit microglial activation may provide insights into 
potential interventions for immune mediated neurodegenerative diseases. In 
general, the inhibition of microglial activation has been characterized by down 
regulation of proinflammatory cytokines and NO. 
RA is an active metabolite of vitamin A. It acts through a family of nuclear 
transcription factors known as retinoid receptors (Marill et al. 2003). While the 
principal effects of RA on target cells are inhibition of proliferation and induction 
of differentiation (Maden 2002), it has also been shown that RA exhibits 
immunomodulatory and anti-inflammatory activities in various cell types 
(Mathew and Sharma 2000).  For example, RA has been shown to induce TNF-α 
mRNA destabilization in an RXR dependent manner in the rat hepatic 
macrophages (Motomura et al. 2001). Further, RA also reduced NO production 
induced by IL-1 and IFN-γ in rat pancreatic beta cells (Kang et al. 2004). In the 
present study, RA has been found to inhibit the expression of TNF-α and iNOS in 
activated microglia. 
   I have also investigated the mechanisms by which RA inhibits the TNF-α and 
iNOS expression in activated microglia. Previous studies have suggested that RA 
plays a role in regulation of the activation of JNK MAP kinase signaling pathways 
in cardiomyocytes (Palm-Leis et al. 2004). In the present study, RA has been 
found to inhibit LPS-induced rapid phosphorylation of JNK MAP kinase in 
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microglial cells. JNK has been implicated as an essential mediator of 
pro-inflammatory functions such as TNF-α production in microglial cells 
(Waetzig et al. 2005). Inhibition of JNK suppresses the c-Jun phosphorylation and 
subsequent transcription of c-Jun/AP-1 target genes, including TNF-α and iNOS  
(Waetzig  et al. 2005). In the present study, the inhibition of TNF-α and iNOS 
expression by RA in activated microglia appears to be mediated via inhibition of 
JNK MAP kinase phosphorylation.   
   MAP kinase activity is negatively regulated by MAPK phosphatases (MKPs) 
(Clark 2003). RA appears to inhibit MAP kinases activity in activated microglia 
by inducing MKP-1, a member of the MKP family, as it was found to induce the 
expression of MKP-1 in LPS-stimulated microglial cells. It has also been reported 
that RA inhibits the proliferation of various cell types including cardiomyocytes 
and hepatocytes in different experimental conditions by MKP-1 mediated MAP 
kinases inactivation (Palm-Leis et al. 2004). Taken together, it is suggested that 
RA acts on the activated microglia by inducing the expression of MKP-1 which 
negatively regulates the JNK phosphorylation, resulting in inhibition of 
neurotoxicity and possibly, proliferation of microglia, 
It has also been shown that RA inhibits the expression of iNOS and TNF-α by 
down-regulating NF-κB transcriptional activity.  A mechanistic link between 
iNOS and NF-κB has been demonstrated as the iNOS promoter contains several 
NF-κB binding sites (Xie et al. 1993). This link has been further confirmed as the 
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iNOS expression was shown to be inhibited by downregulation of NF-κB activity 
(Pahan et al. 1997). In addition, it has been shown that NF-κB forms a 
transcriptionally inactive complex with retinoid-activated RXR (Na et al. 1999). 
The RXR forms a heterodimeric complex of RARβ/RXR (Soprano and Soprano 
2002) through which RAR-dependent signaling is transduced. Taken together, it 
was suggested that RA acts on the microglia by inducing the expression of RARβ 
which downregulates the NF-κB transcriptional activity, thereby iNOS expression 
is inhibited in activated microglia treated with RA. In addition, RA-induced 
inhibition of TNF-α expression in the microglia is likely to be NF-κB dependent 
as it has been reported that inhibition of active NF-κB nuclear translocation by the 
SN-50 peptide prevents the Aβ-stimulated increase of TNF-α promoter activity 
(Combs et al. 2001)  
TGF-β1 acts as an immunosuppressor and inhibits the production of 
inflammatory cytokines by the stimulated microglia (Chao et al. 1995). RA has 
been shown to induce TGF-β1 expression in the various cell types (Defacque et al. 
1999). I have also shown that upregulation of TGF-β1 expression observed in the 
activated microglia treated with RA could contribute to the inhibition of iNOS 
expression (Dheen et al. 2005), via downregulation of NF-κB transcriptional 
activity (Xie et al. 1994) as TGF-β1 has been reported to increase the expression 




4.2.2. RA inhibits GM-CSF-induced microglia proliferation by suppressing the 
cell cycle related protein. 
  Microglia proliferation plays an important role in various neurological 
diseases such as trauma (Urrea et al. 2007) and ischemia (Denes et al. 2007). 
Although the microglial proliferation is elicited by neuronal damage and 
contributes to neuroprotection in some circumstances (Denes et al. 2007), it has 
been widely accepted that the release of neurotoxic mediators by microglia in turn 
contributes to the pathogenesis of neurological diseases. Hence, understanding the 
mechanisms that inhibit microglial proliferation would provide a new therapeutic 
strategy for treatment of neuroinflammation associated disorders in the CNS. 
Microglial proliferation is induced by certain mitogens including GM-CSF, 
M-CSF and some cytokines such as IL-3 (Flanary and Streit 2006). Vitamin E has 
also been shown to facilitate the proliferation of microglia in vitro (Flanary and 
Streit 2006). However, an in vivo analysis revealed that M-CSF and GM-CSF are 
the major mitogens of microglia (Koguchi et al. 2003). GM-CSF regulates several 
cell cycle associated proteins including p27, cylin D, and cyclin E (Koguchi et al. 
2003), which control microglial proliferation. 
The cell cycle progression occurs in 4 phases: G1 phase, S phase, G2 phase, 
and M phase which are controlled by the interaction of several factors including 
cyclins, CDKs and CDKIs. Cyclin D forms a complex by binding with CDK4 and 
CDK6, and regulates the transition from G1 phase to S phase (Bruce et al. 2007). 
Effects of cyclin D/CDK4,6 complex activity are mediated by a gene regulatory 
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protein, E2F, which binds with retinoblastoma protein (Rb), an inhibitor of 
cell-cycle progression (Simin et al. 2004) and transactivates many genes required 
for S phase entry (Bruce et al. 2007). When cells are stimulated to divide by 
extracellular signals, cyclin D/CDK4,6 complexes induce phosphorylation of Rb, 
and release of E2F that activates transcription of S phase genes (Bruce et al. 2007). 
In the present study, I showed that GM-CSF stimulates the proliferation of 
microglia by inducing hyperphosphorylation of Rb and accumulation of E2F-1.  
    RA has been shown to modulate a wide variety of cellular processes; 
however the role for RA in the regulation of microglial proliferation has not been 
explored. In the present study, RA has been found to inhibit the GM-CSF-induced 
microglial proliferation by suppressing the expression of cyclin D1, E2F-1, and 
hyperphosphorylated Rb and increasing the expression of p27, the CDK inhibitor. 
It appears that RA inhibits the proliferation of microglia by inducing cell cycle 
arrest at G1 phase. This is in accordance with the effects of RA in other cell types 
such as breast cancer cells (Wilcken et al. 1996). In human bronchial epithelial 
cells, posttranslational mechanisms have been shown to contribute to the 
suppression of cyclin-CDK complexes by RA (Sueoka et al. 1999). Further, 
suppression of cyclin D1 by RA in microglia exposed to GM-CSF may be 
associated with inhibition of E2F-1 expression, since cyclin D1 is an upstream 
kinase involved in induction of E2F-1 transcription (Jia et al. 2006). 
The suppression of cycin D1 by RA in microglial cells exposed to GM-CSF 
appears to be mediated via induction of p27 which belongs to a family of CDKIs 
Discussion 
 95
and inhibits activity of cyclin/CDK complexes, resulting in cell cycle arrest at 
G1/S phase (Koguchi et al. 2003). Overall, RA induces p27 which suppresses the 
activity of cyclin D1, leading to inhibition of E2F-1 transcription required for the 
induction of expression of S phase genes, thereby resulting in cell cycle arrest at 
G1/S phase in microglial cells exposed to GM-CSF.  
Rb, a negative regulator of cellular proliferation, is one of the target proteins 
of cyclin D-CDK complex. Inactivation of total Rb and activation of Rb 
phosphorylation are critical steps for cell cycle progression. The cyclin D-CDK 
complex activates phosphorylation of Rb, which induces physical dissociation of 
E2F transcription factor from the Rb and expression of genes required for the cell 
cycle at S phase (Gallo and Giordano 2005). Moreover, phosphorylation of Rb is 
also required for inactivation of Rb (Lundberg and Weinberg 1998). In the present 
study, GM-CSF appeared to induce Rb phosphorylation and inactivate total Rb in 
microglial cells. However, RA has been found to reverse these processes as 
observed in other cell types such as human monocytic THP-1 cells (Chen and 
Ross 2004), resulting in arrest of cell cycle progression at G1/S phase in 
microglial cells.  
      Other potential mechanisms may also be involved in the antiproliferative 
effects of RA on microglia as RA has been shown to inhibit microglial expression 
of insulin-like growth factors-1(IGF-1), a mitogen in various cell types ( Dheen et 
al. 2005; Kaur et al. 2006). Further, a systematic investigation may be required to 
understand the antiproliferative effects of RA in microglial cells.   
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Overall, this study demonstrates the mechanisms by which RA inhibits 
proliferation and neurotoxic effect of microglia. RA suppresses the neurotoxic 
effect of microglia by inhibiting the mRNA and protein expression of 
proinflammatory cytokine, TNF-α and iNOS in the primary cultures of rat 
microglia. On the other hand, RA suppresses GM-CSF-induced microglia 
proliferation by altering the expression of cell cycle associated proteins such as 
cyclin D1, E2F-1, Rb and p27. The RA-induced inhibition of TNF-α and iNOS 
syntheses in the activated microglia appears to be mediated via MKP-1-induced 
inhibition of JNK MAPK pathway and downregulation of the NF-κB 
transcriptional activity. Based on the results, it is suggested that RA could be 
considered a potential therapeutic agent that may limit the neuroinflammatory 
response and rapid proliferation of microglia in the neurodegenerative diseases. 
However, further systematic evaluation such as Genearray anaysis is required as 
RA modulates a wide variety of biological processes, including proliferation, 





















  Microglia, the resident immune cells of the CNS, have emerged dramatically 
over the years as a key player engaged in mediating the inflammatory response to 
neuronal cell death in various neurodegenerative diseases including Alzheimer’s 
disease, Parkinson’s disease, prion diseases and HIV-dementia. Activation of 
microglia is considered to be a hallmark of brain pathology. Although they 
normally respond to neuronal damage and remove the damaged cells by 
phagocytosis, it remains controversial whether the reactive microglial cells have 
beneficial or detrimental functions in various neuropathological conditions. 
Mounting evidence indicates that chronic activation of microglia causes 
neurotoxicity through the release of potentially cytotoxic molecules such as 
proinflammatory cytokines including TNF-α and IL-1β, reactive oxygen 
intermediates, proteinases, NO and complement proteins. Therefore, suppression 
of microglia-mediated inflammation has been considered as an important strategy 
in neurodegenerative disease therapy. Several drugs and molecules have been 
shown to repress the microglial activation and to exert neuroprotective effects in 
the various neuropathologic conditions. However, these drugs are not targeted 
specifically against microglial cells and hence may result in various forms of 
undesirable side effects. In view of this, it was suggested that a systematic 
molecular analysis of mode of action of these drugs on microglial cells is required 
to enhance the safe treatment strategy for neurodegenerative diseases. Moreover, 
activation of microglia becomes an increasingly common phenomenon in most of 
the neurodegenerative diseases which continue to be of global importance. The 
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present study was carried out to explore various forms of potential therapeutic 
options (using two drugs, Dex and RA) to inhibit the function of reactive 
microglia which amplify the inflammation-related neuronal injury in 
neurodegenerative diseases. 
In the present study, Dex, a widely used anti-inflammatory and 
immunosuppressive drug in several neurological diseases and RA (a vitamin A 
metabolite) have been found to inhibit microglial activation. Particularly, Dex 
appears to have a dual role: 1. inhibition of inflammatory genes in microglia as 
reported in several studies and 2. inhibition of MCP-1 mediated migration of 
microglia to the inflammation sites in CNS. This study reveals that Dex inhibits 
the synthesis of MCP-1 which is believed to amplify the inflammation process by 
recruiting macrophages and microglia to the inflammatory sites in the CNS, by 
inducing MKP-1 expression which negatively regulates the p38 and JNK MAPK 
pathways (Fig 27). It is suggested that inhibition of MCP-1 by Dex suppresses the 
MCP-1 mediated-migration of microglia to the injury site, so that overpopulation 
of microglia that exacerbates the inflammation around the injury site in CNS is 
controlled. Suppression of the chemotaxic effect of microglia by Dex appears 
complementary to inhibition of inflammatory response of microglia.   
One of the prominent features in the CNS pathology is the rapid microglial 
proliferation which has been implicated in the progression of inflammation and 
neuronal degeneration. As RA has been shown to act as a potent anti-proliferative 
and anti-inflammatory compound in various cell types including peripheral 
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macrophages, monocytes and hematopoietic progenitor cells, I have investigated 
the effects of RA on microglial activation and proliferation in vitro.  The results 
obtained clearly indicate that RA suppresses the activation of microglial cells 
exposed to LPS and β-amyloid peptide in primary culture by inhibiting the 
expression and production of TNF-α and NO. This inhibition of TNF-α and NO 
synthese by RA in the activated microglia appeared to be mediated via inhibition 
of NF-κB translocation which could be caused by upregulation of RAR and 
TGF-β1 gene expression. It has also been shown that RA could inhibit synthesis of 
TNF-α and NO in activated microglia by MKP-1-mediated inhibition of JNK 
MAP kinase pathway (Fig 27). 
Moreover, this study demonstrates that RA inhibits GM-CSF induced 
microglial proliferation by altering the expression of cell cycle associated proteins 
such as cyclin D1, E2F-1, Rb and p27. Based on the results, it is suggested that 
RA could be considered a potential therapeutic agent that may inhibit the 
expansion and activation of microglia in the neurodegenerative diseases. However, 
careful evaluation is needed before RA is considered for the treatment of 
neurodegenerative diseases as it modulates a wide variety of biological processes 







      
Fig 27. An illustration demonstrates that LPS and other stimuli activate microglial 
cells by inducing the release of proinflammatory mediators and chemokines via 
MAPKs i.e., p38 and JNK. Dex inhibits microglial activation and migration by 
suppressing the release of proinflammatory mediators and chemokines via 
induction of MKP-1 which negatively regulates MAPKs. RA binds with its 
receptor complex and inhibits the microglial activation by suppressing the release 
of TNF-α and NO via MKP-1-mediated inhibition of JNK MAP kinase pathway 
and inhibition of NF-κB translocation which could be caused by upregulation of 




Scope for the Future Study 
Microglia, once considered not even to exist or in oblivion in the 50s-70s 
of the last century, have emerged dramatically over the years to be a key player 
engaged in a pivotal role that may lead to a fuller understanding of mechanism of  
various neurodegenerative diseases. Several studies on neurodegenerative diseases 
point to a hypothesis that multiple primary causes for these diseases may be 
ultimately linked to a final common signal transduction pathway involving 
microglial cells, leading to neuroprotection or neurodegeneration. There is ample 
evidence demonstrating the microglial activation and their secretory activity in 
response to various neurodegenerative diseases and remarkably, the response of 
microglial cells to various stimuli is relatively consistent. As far as can be 
ascertained, the majority of the studies on expression and secretory patterns of 
cytokines and chemokines in activated microglial cells has been based on in vitro 
analysis. There is an apparent lack of information on the signaling pathways that 
are elicited in microglial cells when activated in vivo. This direction of study is of 
clinical importance as it could open up new vistas of research to develop safe 
mode of therapeutic strategy for neurodegenerative diseases.  
Several drugs and molecules have been shown to suppress the microglial 
activation in chronic pathologic conditions. It needs to be emphasized that these 
drugs are not targeted specifically against the microglial cells and hence may 
result in various forms of undesirable side effects. A systematic molecular analysis 
of mode of action of these drugs on microglial cells would greatly enhance the 
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treatment strategy for neurodegenerative diseases. Moreover, activation of 
microglia becomes an increasingly common phenomenon in most of the 
neurodegenerative diseases which continue to be of global importance. Thus, 
future research needs to focus on identification of microglia specific proteins that 
would be of great therapeutic value and may serve as useful biomarkers for 
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alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory 











Figs. 1 A-C. Confocal images of microglia labeled with lectin (green) and nuclear 
marker, PI (red). In the control (A), microglial cells exhibit dendritic morphology 
with many highly ramified processes (arrows). After stimulation with LPS for 6 h, 
the cells transformed into amoeboid cells which appear hypertrophic and contain 
abundant cytoplasmic inclusions (arrows, B). Majority of the microglial cells 






















Figs. 2 A-C. Real time RT-PCR analysis demonstrating the inhibitory effects of 
Dex on MCP-1 mRNA expression in microglia treated with LPS. A. The PCR 
product of MCP-1 gene (91 bp) amplified in microglial cells is shown. B. The 
melting curve of the real time RT-PCR with a single peak shows the specificity of 
the product. C. After LPS treatment for 6 h, MCP-1 mRNA expression level is 
elevated to about 22 folds in comparison to that of control. Dex decreased the 
mRNA expression of MCP-1 significantly in microglial cells treated with LPS. 
Data represent mean±SD (n=4 independent experiments). Control vs LPS treated 


















































Fig. 3:  Confocal images of microglia showing MCP-1 immunoreactivity (green) 
and PI (red), the nuclear marker. Note that MCP-1 positive cells are hardly 
detectable in the untreated microglial cultures (A), while majority of the 
microglial cells exhibit MCP-1 immunoreactivity in cultures treated with LPS (B, 
arrows). Dex decreased the staining intensity of MCP-1 immunoreactivity and the 
number of MCP-1 positive cells in the microglial cultures treated with LPS (C). 




















Fig. 4 Analysis by ELISA shows that MCP-1 release is increased significantly in 
microglial cultures treated with LPS; the increase is inhibited by Dex. Data 
represent mean±SD (n=3 independent experiments). Significance of difference 


































Fig. 5 Western blot analysis shows that Dex inhibits the phosphorylation of JNK 
in microglia treated with LPS. A: LPS treatment induces rapid and 
time-dependent phosphorylation of JNK in microglial cells. The induction of 
phosphorylation of JNK is significantly reduced at 15min, 30min, 1h in microglial 
cells pre-treated with Dex, 2h prior to LPS stimulation. Lower panels of Western 
blot show no differences in total JNKs.  Blots are representative of three 
independent time course studies. B: Data are presented as signal intensity of 
phospho-JNK relative to total JNK (mean ± SD). Significant difference between 
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Fig. 6 Western blot analysis shows that Dex inhibits the phosphorylation of p38 in 
microglia treated with LPS.  A: LPS treatment induces rapid and time-dependent 
phosphorylation of p38 in microglial cells. The induction of phosphorylation of 
p38 is significantly reduced at 15min, 30min, 1h in microglial cells pre-treated 
with Dex, 2h prior to LPS stimulation. Lower panels of Western blot show no 
differences in total p38.  Blots are representative of three independent time 
course studies. B: Data are presented as signal intensity of phospho-p38 relative to 
total p38 (mean ± SD). Significant difference between LPS and LPS plus Dex 
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Fig. 7 Western blot analysis shows that Dex does not inhibit the phosphorylation 
of ERK1/2 in microglia treated with LPS. A: Phosphorylation of ERK1/2 is also 
induced in microglial cells treated with LPS, but it appears to be unaltered by Dex 
treatment. B: Data are presented as signal intensity of phospho-ERK1/2 relative to 
total ERK1//2 (mean ± SD). There is no significant difference between LPS and 
LPS plus Dex group. 
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Fig. 8 A-C: Confocal images showing microglia immunostained with the 
N-terminal phosphorylated c-Jun (phospho-c-Jun, red) and lectin (green) and 
counterstained with DAPI (blue). Note the enhanced nuclear expression of 
phospho-c-Jun (pink, arrows) in microglia treated with LPS for 30 min (B).  C. 
Dex treatment 2h prior to LPS decreases phospho-c-Jun expression significantly 
in microglial cells (arrows). D. Quantitative analysis shows the decrease in 
number of phsophorylated c-Jun immunoreactive cells in microglia cultures 
treated with LPS for 30min and Dex for 2h prior to LPS treatment. Data represent 
mean±SD (n=3 independent experiments). Significance of difference (control vs 























































Fig. 9 Analysis by ELISA shows that LPS-induced release of MCP-1 is partly 
suppressed by pre-incubation of microglial cells for 30min with SP600125, the 
JNK inhibitor (24%), and SB202380, the p38 inhibitor (40%). Data represent 
mean±SD (n=4 independent experiments). Significance of difference (control vs 




































Fig. 10 Analysis by MTS shows that neither SP600125 nor SB202380 alone has 
effects on microglial cell viability. Data respresesnt mean±SD (n=4 independent 
experiments). There is no significant difference between control and JNK inhibitor 
SP600125 (1μm) treated cultures or between control and SB202380 (1μm) treated 





































Fig. 11 Real time RT-PCR analysis demonstrates that Dex increases MKP-1 
mRNA expression in microglia treated with LPS. A. The PCR product of MKP-1 
gene (302 bp) amplified in microglial cells is shown. B. The melting curve of the 
real time RT-PCR with a single peak shows the specificity of the product. C. Real 
time RT-PCR analysis shows that pre-incubation of microglial cells with Dex, 2h 
prior to LPS treatment enhances MKP-1 mRNA expression significantly. MKP-1 
mRNA expression level is elevated to 27 folds or 19 folds in microglial cells 
treated with LPS for 1h or with Dex alone for 2h respectively in comparison to 
that of control.. Dex treatment further increases MKP-1 gene expression to 149 
folds in the LPS-treated microglia. Data represent mean±SD (n = 4 independent 
experiments). Significant (control vs LPS, control vs Dex, LPS vs LPS+Dex) is 




















































Fig. 12:  Western blot analysis shows that Dex increases MKP-1 protein 
expression in LPS-treated microglia. A. LPS stimulated MKP-1 protein 
expression in microglial cells, reaching its maximal level by 1-2 h, and then 
decreased to basal level. Pre-incubation of microglial cells with Dex 2h prior to 
LPS treatment further enhances MKP-1 protein expression significantly at almost 
all the time points studied. B. Data represent the mean signal intensity of MKP-1 
relative to control (mean ± SD, n= 3 independent experiments). Significant 
difference between LPS and LPS plus Dex group is indicated by *p<0.05. 
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Fig. 13A: Western blot analysis shows that MKP-1 protein expression level 
induced by Dex alone in microglial cells is constant at all time points studied. B. 
Data represent the mean signal intensity of MKP-1 relative to control (mean±SD, 
n= 3 independent experiments). 
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Fig. 14: The phosphorylation of p38 and JNK is induced in activated microglial 
cells exposed to Dex by blocking of MKP-1 induction with triptolide. Triptolide 
alone has no effect on phosphorylation of MAPKs. Phosphorylation of JNK and 
p38 MAPKs is induced in microglial cells treated with LPS for 1h, and this 
induction is suppressed by Dex treated for 2h prior to LPS treatment. The 
inhibitory effect of Dex is reversed by pretreatment of microglial cells with 
triptolide. Neither Dex nor triptolide altered ERK1/2 phosphorylation.  The blot 
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Fig. 15: The quantitative analysis by real time RT-PCR shows that triptolide 
pretreatment increased MCP-1 mRNA expression to 2.9 folds in microglial cells 
treated with LPS and Dex for 6h.  Data represent mean±SD (n= 4 independent 








































Fig. 16A-C Dex inhibits CCR2 mRNA expression in activated microglia. A. The 
PCR product of CCR2 gene (233bp) amplified in microglial cells is shown. B. 
The melting curve of the real time RT-PCR with a single peak shows the 
specificity of the product. C. Real time RT-PCR analysis shows that the CCR2 
mRNA expression level is increased to 11 folds in microglia treated with LPS, 
when compared to that of control.  Dex decreased the mRNA expression level of 
CCR2 by 32% in the LPS-treated microglia. Data represent mean±SD (n=4 
independent experiments). Control vs LPS treated cultures; LPs vs LPS+Dex 



















































Fig. 17A-C Confocal images of microglial cells showing CCR2 immunoreactivity 
(green) and nuclear marker, PI (red). In the control (A), CCR2 positive cells are 
hardly detectable. The CCR2 immunoreactivity appears to be markedly increased 
in majority of the microglial cells treated with LPS for 6h (B, arrows). Dex 
decreased the staining intensity and the number of CCR2 positive cells in the 



















Fig. 18  In vitro chemotaxis assay reveals that MCP-1 induces the migration of 
microglia in a dose-dependent manner. The maximum effect of MCP-1 on 


































Figs. 19  The optimal dilution of media derived from the DMEM, control, LPS 
and LPS+Dex treated microglial cultures was determined by measuring the 
chemotaxic effect of serial dilutions (1, 1/2, 1/4 and 1/8). ¼ dilution was 






































Fig. 20: Effects of Dex, recombinant MCP-1, anti-MCP-1 antiserum and unrelated 
antiserum on LPS-stimulated migration of microglia. A. Chamotaxis assay results 
show that a few violet-stained microglia (arrows) transmigrate through the 
membrane of insert in a transwell chamber containing DMEM medium. 
Optimised condition medium derived from LPS-treated microglial cultures attract 
more microglial cells than the control medium.  The numbers of transmigrated 
microglia are markedly reduced in Dex+LPS treated medium. The inhibitory 
effect of Dex on chemotaxis is partly reversed when the medium is supplemented 
with 62.5ng/ml of recombinant MCP-1 protein. The medium of LPS treated 
culture with rabbit anti-MCP-1 antiserum attracts less microglia than that from 
LPS+unrelated antiserum (rabbit anti-iNOS). B. Quantitative analysis shows that 
LPS-induced migration is suppressed significantly by both Dex and anti-MCP-1 
antiserum. Data represent the mean percentage of migrated cells per microscopic 
field relative to spontaneous migration towards the DMEM medium (0.5% BSA). 







































































Fig. 21 Confocal images of microglia showing TNF-α and iNOS 
immunoreactivity (green) and nuclear marker, PI (red). In the control microglia 
cultures (A, D), TNF-α and iNOS positive cells are hardly detectable. The number 
of TNF-α and iNOS positive cells are increased in the cultures treated with LPS 
for 6 h (B, E). These cells appear to be increased in size and show abundant 
cytoplasm with numerous cytoplasmic inclusions (arrows). RA decreased the 
staining intensity and the number of both TNF-α and iNOS positive cells in the 
primary microglia cultures treated with LPS (C, F). These cells appear smaller 





















Fig. 22 Western blot shows that RA inhibited the LPS-induced expression of 
TNF-α and iNOS proteins in microglia (A,B). C. TNF-α and NO production by 
microglia either unstimulated or incubated with LPS, RA or LPS+RA for 6 h was 
determined by ELISA and nitrite assay, respectively. The results show that RA 
inhibited the release of TNF-α and NO by LPS-treated microglia. Results are 
expressed as percentage of change compared with the control. Data represent 
mean ± SD (n = 3). Significant differences between LPS-treated cultures and 













Fig. 23 Western blot analysis shows that RA inhibits JNK phosphorylation and 
induces MKP-1 expression in LPS-treated microglia. LPS treatment for30 min 
induced the expression of phosphorylated JNK and pre-incubation with RA 2h 
prior to LPS treatment inhibited the phosphorylation of JNK. The total JNK 
expression appears to be unaltered by LPS and RA. LPS treatment for 30min also 
induced MKP-1 expression, which was further enhanced when microglial cells 
were pre-incubated with RA prior to LPS treatment. Each blot represents three 
independent experiments.   
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Fig. 24. RA inhibits GM-CSF-induced microglial proliferation as revealed by 
BrdU incorporation.  A. Confocal image showing microglia immunostained with 
BrdU (red) and counterstained with lectin (green). B. Note the increased number 
of BrdU positive cells (arrows) in microglia culture treated with GM-CSF for 24h. 
C. RA treatment together with GM-CSF decreased the number of BrdU positive 
cells significantly in microglial culture. D. Quantitative analysis shows the 
decrease in number of BrdU immunoreactive cells in microglia cultures treated 
with RA and GM-CSF for 24h. Data represent mean±SD (n=3 independent 
experiments). Significance of difference (control vs GM-CSF and GM-CSF vs 









































Fig. 25  MTS analysis further confirms the inhibitory effect of RA on microglial 
proliferation. The number of microglial cells is increased in primary culture 
incubated with GM-CSF for 1 day, whereas the increase is arrested when the 
culture is exposed to RA together with GM-CSF. RA itself has no effect on the 
proliferation of microglia. Data represent mean ± SD (n=3 independent 
experiments). Significance of difference (control vs GM-CSF and GM-CSF vs 










































Fig. 26 Western blot analysis of the effects of RA on expression of cell cycle 
related proteins in microglia treated with GM-CSF. RA suppressed the expression 
of cyclin D1 and E2F-1 induced by GM-CSF in microglia. In contrast, expression 
of P27, cyclin-dependent kinase inhibitory protein is decreased in microglia 
treated with GM-CSF and restored by RA. GM-CSF also increased the level of 
phosphorylated Rb and decreased the level of total Rb in microglia.. RA 
suppressed the phosphorylation of Rb and restored the level of total Rb in 
microglia exposed to GM-CSF. Expression of tubulin confirms the equal amount 
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